Biphasic regulation of Yes-associated Protein (YAP) cellular localization, phosphorylation and activity by G protein-coupled receptor agonists in intestinal epithelial cells: a novel role for protein kinase D (PKD)

Jia Wang1, James Sinnett-Smith1,2,4, Jan V. Stevens1, Steven H. Young1,4 and Enrique Rozengurt1,2,3,4 *

1Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, 2CURE: Digestive Diseases Research Center, 3Molecular Biology Institute, University of California at Los Angeles and 4VA Greater Los Angeles Health Care System

Running Title: Protein kinase D regulation of YAP signaling

To whom correspondence should be addressed: 900 Veteran Avenue, Warren Hall Room 11-124, Department of Medicine, UCLA School of Medicine, Los Angeles, CA 90095-1786
Telephone: 310-794-6610; Email: erozengurt@mednet.ucla.edu

Keywords: G protein-coupled receptors; Angiotensin II; IEC-18 cells; PKD family inhibitors; CRT0066101 and kb NB 142-70; PKC.

ABSTRACT

We examined the regulation of Yes-associated Protein (YAP) localization, phosphorylation and transcriptional activity in intestinal epithelial cells. Our results show that stimulation of intestinal epithelial IEC-18 cells with the G protein-coupled receptor (GPCR) agonist angiotensin II (ANG II), a potent mitogen for these cells, induced rapid translocation of YAP from the nucleus to the cytoplasm (within 15 min) and a concomitant increase in YAP phosphorylation on Ser127 and Ser397. ANG II elicited YAP phosphorylation and cytoplasmic accumulation in a dose-dependent manner (ED50 = 0.3 nM). Similar YAP responses were provoked by stimulation with vasopressin or serum. Treatment of the cells with the protein kinase D (PKD) family inhibitors CRT0066101 and kb NB 142-70 prevented the increase in YAP phosphorylation on Ser127 and Ser397 via Lats2, YAP cytoplasmic accumulation and increase in the mRNA levels of YAP/TEAD-regulated genes (Ctgf, Areg). Furthermore, siRNA-mediated knockdown of PKD1, PKD2 and PKD3 markedly attenuated YAP nuclear-cytoplasmic shuttling, phosphorylation at Ser127 and induction of Ctgf and Areg expression in response to GPCR activation. These results identify a novel role for the PKD family in the control of biphasic localization, phosphorylation and transcriptional activity of YAP in intestinal epithelial cells. In turn, YAP and TAZ are necessary for the stimulation of the proliferative response of intestinal epithelial cells to GPCR agonists that act via PKD. The discovery of interaction between YAP and PKD pathways identifies a novel crosstalk in signal transduction and demonstrates, for the first time, that the PKDs feed into the YAP pathway.

The proliferation of the epithelial cells of the intestinal mucosa is a tightly regulated process modulated by a broad range of regulatory peptides, neurotransmitters, bioactive lipids and differentiation signals (1). Many of these stimuli initiate their characteristic effects in their target cells through G protein-coupled receptors (GPCRs) (2-6). Despite their fundamental importance for understanding intestinal homeostasis, wound healing and pathogenesis of human diseases, the intracellular signal transduction mechanisms that mediate GPCR-
induced proliferation of intestinal epithelial cells remain incompletely understood.

The highly conserved Hippo pathway, originally identified in *Drosophila*, is attracting intense interest as a key regulator of organ-size, tissue regeneration, tumorigenesis and GPCR signaling (7). Canonical Hippo signals in vertebrate cells are transduced through a core serine/threonine kinase cascade wherein Mst1/2 kinases, in complex with the scaffold Sav1, phosphorylate and activate Lats1/2 (large tumor suppressor 1/2), in complex with its regulatory protein MOB1/2 (8). In addition to Mst1/2, Hpyy/MAP4Ks were recently identified as alternative kinases that phosphorylate Lats1/2 (9,10). In turn, Lats1/2 phosphorylates the transcriptional co-activators Yes-Associated Protein (YAP) and WW-domain-containing Transcriptional co-Activator with PDZ-binding motif (TAZ), two major downstream effectors of the Hippo pathway. The intracellular distribution of YAP and TAZ is highly dynamic, exhibiting rapid nuclear-cytoplasmic shuttling. The phosphorylation of YAP and TAZ by Lats1/2 is widely thought to restrict their activity, cellular localization and stability. In the absence of phosphorylation, YAP localizes to the nucleus where it binds and activates the TEA-domain DNA-binding transcription factors thereby stimulating the expression of proliferative and anti-apoptotic genes. Several studies indicate that YAP acts as a context-specific oncogene (11) and that the Hippo pathway inhibits its activity. Despite intense interest in this novel pathway, many important questions relating to its function remain unanswered: 1) the mechanism(s) by which upstream signals feed into the Hippo cascade remain incompletely defined; 2) YAP not only acts as a transcriptional co-activator in the nucleus but also mediates biological functions in other cellular locations, including the cytoplasm (12,13); 3) YAP cross-talks with other important signaling pathways but the biological outcome (positive or negative) of these interactions remains unclear and is likely context-dependent. Even at the most fundamental level, the precise role of YAP in intestinal epithelial cell proliferation remains incompletely understood, as evidence for both growth-stimulatory and growth-suppressive roles of YAP/TAZ has been presented (14-17).

G protein-coupled receptor (GPCR) agonists act as important signals upstream of the Hippo/YAP/TAZ pathway. Protein kinase D (PKD), a protein kinase family upstream of the CAMK group (18), has emerged as a prominent downstream signal induced by GPCRs that function through Gq/11, Gz12, Gzi, and Rho (18-26). PKD1, the founding and most studied member of the PKD family (27,28) which is comprised by PKD1, PKD2 and PKD3, is rapidly activated through protein kinase C (PKC)-mediated phosphorylation of Ser744 and Ser748 in the PKD1 activation loop (29-32). PKD1 catalytic activation within cells leads to its auto-phosphorylation at Ser916 and Ser748 (33-36). Rapid PKC-dependent PKD1 activation is followed by a late, PKC-independent phase of activation induced by GPCR agonists (35-37). Accumulating evidence demonstrate that the PKD family plays an important role in a variety of cellular processes and activities, including cytoskeletal organization, gene expression, cell migration and proliferation (19). In intestinal epithelial cells, PKD1 activation mediates migration and proliferation both *in vitro* and *in vivo* (36,38). Accordingly, multiple growth-promoting stimuli rapidly activate PKD1 catalytic activity in intestinal epithelial cells (23,36,38-40) through activation loop phosphorylation (30,35-37). Furthermore, transgenic mice that express elevated PKD1 protein in intestinal epithelial cells display a marked increase in DNA-synthesizing cells in their intestinal crypts and a significant increase in the length and total number of cells per crypt (36). Collectively, these results support the notion that PKD1 signaling is a novel element in the pathway leading to proliferation of intestinal epithelial cells *in vitro* and *in vivo*. The mechanisms downstream of PKD1, however, remain to be elucidated and, in particular, crosstalk between PKD and YAP has not been identified either in intestinal epithelial or in any other cell type.

The results presented here identify a novel temporal pattern of nuclear-cytoplasmic shuttling of endogenous YAP in response to GPCR stimulation in intestinal epithelial cells. Specifically, we show that GPCR activation elicits a rapid but transient YAP phosphorylation and localization to the cytoplasm followed by a second phase involving YAP re-localization to the nucleus and stimulation of YAP/TEAD-regulated genes. Further studies demonstrate, for the first time,
crosstalk between PKD and Lats/YAP/TEAD signaling pathways. Based on the results presented here, we conclude that the PKD family controls the localization, phosphorylation and transcriptional co-activator activity of YAP in intestinal epithelial cells. In turn, YAP is necessary for the stimulation of the proliferative response of intestinal epithelial cells to GPCR agonists that act via PKD. Collectively, our results identify, for the first time, a novel crosstalk between YAP and PKD signaling pathways leading to biphasic regulation of YAP in intestinal epithelial cells.

RESULTS

Identification of a novel pattern of YAP nuclear-cytoplasmic shuttling in intestinal epithelial cells.

In order to examine the regulation of YAP cellular localization, phosphorylation and activity in intestinal epithelial cells, we used the non-transformed IEC-18 and IEC-6 cells (41,42), which were derived from neonatal rat small intestine and have characteristics of crypt-type epithelial cells. These cells endogenously express Gq/11-coupled receptors for angiotensin II (ANGII) and vasopressin (23,39,40,43-46) and have been extensively used as a model system to examine signal transduction pathways in response to GPCR activation (23,36,38,39,43-45,47). ANGII and vasopressin act as potent growth factors for IEC-18 and IEC-6 cells (23,39,43-45,47). Because the levels of YAP/TAZ influence their association with transcriptional cofactors especially when expressed at elevated levels, we studied the localization, phosphorylation and activity of the endogenous YAP protein.

Initially, we determined the localization of YAP in confluent and quiescent cultures of IEC-18 cells (23,36) after various times of stimulation with or without ANGII. In un-stimulated cells, YAP was localized to the nucleus and cytoplasm, as revealed by immunofluorescence staining using antibodies that detect total YAP. In contrast to results presented in other cells types, stimulation of IEC-18 cells with ANG II induced a rapid and dramatic translocation of YAP from the nucleus to the cytoplasm (Fig. 1, A). Using the CellProfiler software for image analysis, we quantified the nuclear to cytoplasmic ratio of YAP immunofluorescence in thousands of individual cells. This analysis revealed that nuclear YAP declined steeply (within 15 min) and transiently in response to ANG II stimulation (Fig. 1 B). YAP re-localized to the nucleus after 2 h of stimulation. The histogram representing the distribution of control cells as a function of their nuclear to cytoplasmic ratio of YAP followed a normal distribution, (Fig. 1 C, open bars). Treatment of IEC-18 cells with ANG II for 30 min caused a marked shift of the distribution to the left (Fig. 1 C, closed bars), reflecting YAP translocation from the nucleus to the cytoplasm in most cells of the population. Rapid nuclear-cytoplasmic shuttling of YAP was also provoked by stimulation of IEC-18 cells with the GPCR agonist vasopressin (39) or by serum growth factors (Fig. 1 D).

In dose-response studies, ANGII induced rapid cytoplasmic localization of YAP in IEC-18 cells even at concentrations lower than 1 nM (Fig. 2 A). Quantification by image analysis indicates that half-maximal effect of ANG II was elicited at 0.3 nM (Fig. 2 B), suggesting that this agonist regulates YAP localization in intestinal epithelial cells via its specific endogenous GPCRs. Indeed, pretreatment of IEC-18 cells with the selective ANG II type 1 (AT_1) receptor antagonist losartan completely blocked ANG II-induced YAP nuclear extrusion (Fig. 2 C). Surprisingly, our results revealed that mitogenic stimuli, including GPCR agonists and serum growth factors induce biphasic re-distribution of YAP in intestinal epithelial IEC-18 cells characterized by rapid cytoplasmic localization followed by subsequent nuclear re-localization, a temporal pattern distinct from that induced by mitogenic stimuli in other cell types.

**GPCR agonists induce rapid increase in the phosphorylation of YAP at Ser^{127} and Ser^{597} in IEC-18 cells.**

We next determined whether ANG II-induced activation of endogenous AT_1 receptors modulates YAP phosphorylation at Ser^{127}, a highly conserved residue located within a consensus sequence phosphorylated by Lats1/2 (HXRXXS). Cultures of IEC-18 cells were stimulated with ANGII for various times and cell lysates were analyzed by Western blotting with an antibody that detects the phosphorylated state of YAP at Ser^{127}. ANGII induced a rapid and transient increase in YAP phosphorylation at Ser^{127} in intestinal epithelial cells (Fig. 3, A). An increase in YAP phosphorylation was detected within 5 min of stimulation and reached a maximum within 15 min. The time-course of the increase in YAP...
phosphorylation coincided with the rapid cytoplasmic localization of YAP (shown in Fig. 1).

In order to examine further whether YAP localization and phosphorylation of Ser\textsuperscript{127} are tightly coupled in IEC-18 cells, cultures of these cells were challenged with increasing concentrations of ANG II for 30 min and cell lysates were analyzed by Western blotting to detect the phosphorylated state of YAP at Ser\textsuperscript{127}. As shown in Fig. 3 B, ANG II elicited YAP phosphorylation at Ser\textsuperscript{127} in a dose-dependent manner. Half-maximal stimulation was achieved at ~0.3 nM, implying that the dose-responses of ANG II for eliciting rapid increase in YAP phosphorylation at Ser\textsuperscript{127} (Fig. 3 C) and cytoplasmic localization (shown in Fig. 2 B) are virtually superimposable.

In addition to Lats1/2, mammalian NDR1/2 kinases have recently been proposed to phosphorylate YAP on Ser\textsuperscript{127} in the intestinal epithelial cells (48). Interestingly, the NDRs did not phosphorylate YAP at Ser\textsuperscript{397} (48), a residue targeted by Lats1/2 (49). Consequently, we determined whether GPCR stimulation induces YAP phosphorylation at Ser\textsuperscript{397}. Treatment with ANGII induced a rapid (Fig. 3 A) and dose-dependent (Fig. 3 B) increase in YAP phosphorylation at Ser\textsuperscript{397}. Indeed, the dose-response of ANG II for eliciting YAP phosphorylation at Ser\textsuperscript{127} and Ser\textsuperscript{397} were identical (Fig. 3 C).

We verified that the bands detected with the phospho-specific Ser\textsuperscript{127} (pS127) and Ser\textsuperscript{397} (pS397) antibodies correspond to endogenous YAP since Western blot analysis of YAP immunoprecipitates with the pS127 or pS397 antibodies revealed a single band that co-migrated with YAP (Fig. 3 D). In addition, the bands detected with the pS127 and pS397 antibodies were completely extinguished by siRNA-mediated knockdown of YAP (Fig. 3 E).

The results imply that stimulation of IEC-18 cells with ANG II induces rapid and transient increase in YAP phosphorylation at Ser\textsuperscript{127} and Ser\textsuperscript{397} that coincided with the rapid re-distribution of this transcriptional co-activator from the nucleus to the cytoplasm.

**GPCR agonists induce rapid increase in the phosphorylation of YAP in IEC-6 and Caco-2 intestinal epithelial cells.**

Rapid cytoplasmic localization and phosphorylation of YAP in response to GPCR agonists was not restricted to IEC-18 cells but detected in other intestinal cells, including IEC-6 cells stimulated with ANG II (Fig. 4 A) and in human epithelial colorectal adenocarcinoma Caco-2 cells challenged with serum (Fig. 4 B). These findings are of great interest as they indicate that rapid translocation of YAP from the nucleus to cytoplasm and phosphorylation occurs in a variety of intestinal epithelial cells stimulated to proliferate by multiple stimuli.

Because our results with mitogen-stimulated intestinal epithelial cells contrasted sharply with previous reports typically using HEK293 cells, we also examined YAP localization and phosphorylation in these cells, using our reagents and experimental conditions. We readily confirmed that YAP was in the cytoplasm of densely plated HEK 293 cells and that serum (or LPA) stimulation of these cells promoted rapid YAP nuclear import and dephosphorylation at Ser\textsuperscript{127} (Fig. 4 C). Indeed, the decrease in YAP phosphorylation at Ser\textsuperscript{127} induced by serum or LPA was striking after 30 min of stimulation and persisted for at least 4 h (Fig. 4 C). Similarly, stimulation of human pancreatic cancer PANC-1 cells with neurotensin, a neuropeptide that acts through endogenously expressed GPCRs in these cells (50,51), promoted rapid YAP nuclear import and dephosphorylation at Ser\textsuperscript{127} (Fig. 4 D). The results substantiate that growth-promoting GPCR agonists and serum growth factors induce a distinct pattern of YAP intracellular redistribution and phosphorylation in intestinal epithelial cells, clearly different from the sequence of these events observed in either HEK 293 or PANC-1 cells.

**Role of Akt, PKA and PKC in mediating intracellular translocation and phosphorylation of YAP in intestinal epithelial cells.**

As a first step to identify upstream pathways that mediate rapid GPCR-induced YAP nuclear-cytoplasmic shuttling in intestinal epithelial cells, we tested small-molecule inhibitors targeting kinases. Given the purported role of Akt in Hippo pathway regulation in other cell types (52,53), we initially determined the effect of the Akt inhibitor GSK690693 (54) on YAP re-localization and phosphorylation. Treatment of intact IEC-18 cells with 2.5 µM GSK690693 blocked the rapid cytoplasmic accumulation of YAP induced by stimulation with ANG II (Fig. 5 A). Image analysis revealed that exposure to GSK690693 completely prevented the decrease in the nuclear to cytoplasmic ratio of YAP induced by ANG II (Fig. 5 B). Similar
results were obtained when IEC-18 cells were stimulated with vasopressin or serum instead of ANG II (not shown). Furthermore, GSK690693 inhibited YAP phosphorylation at both Ser\textsuperscript{127} and Ser\textsuperscript{397} in intestinal epithelial IEC-18 cells (Fig. 5 C).

In order to confirm the specificity of the effects obtained with GSK690693, we tested other Akt inhibitors, including GDC-0068, a structurally unrelated ATP-competitive inhibitor of the Akt family (55) and MK2206, an allosteric inhibitor that binds to the PH domain of the Akts (56). Surprisingly, neither GDC-0068 at 2.5 \( \mu \text{M} \) nor MK2206 at 5 \( \mu \text{M} \) had any effect on the cytoplasmic translocation of YAP induced by ANG II in IEC-18 cells (Fig. 5 A and B). Furthermore, these compounds did not prevent YAP phosphorylation at Ser\textsuperscript{127} or Ser\textsuperscript{397} (Fig. 5 C). We verified that exposure of IEC-18 cells to either 2.5 \( \mu \text{M} \) GDC-0068 or 5 \( \mu \text{M} \) MK2206 inhibited Akt activation as effectively as GSK690693, as scored by the phosphorylation of PRAS40 phosphorylation at Thr\textsuperscript{246}, a residue targeted by Akt (Fig. 5 C). These results implied that GSK690693 potently inhibits YAP cytoplasmic localization and phosphorylation in IEC-18 cells through an Akt-independent pathway.

In addition to Akt, GSK690693 also inhibits PKA and novel PKCs (57). Therefore, we tested whether inhibition of these kinases has any effect on YAP localization and/or phosphorylation in IEC-18 cells. Exposure to H89 at 10 \( \mu \text{M} \), a concentration that suppresses PKA activity within intact IEC-18 cells (our unpublished results), did not produce any detectable effect on either YAP localization (Fig. 5 D; image analysis in 5 E) or phosphorylation (Fig. 5 F) in response to ANG II. In sharp contrast, treatment with the PKC inhibitors Gö6983 or GFI prior to ANG II stimulation greatly attenuated YAP cytoplasmic localization (Fig. 5 D; image analysis in 5 E) and phosphorylation at both Ser\textsuperscript{127} and Ser\textsuperscript{397} (Fig. 5 F). These results implied that PKCs mediate transient YAP re-localization and phosphorylation in GPCR-stimulated IEC-18 cells.

**PKDs mediate intracellular translocations and phosphorylation of YAP.**

We previously demonstrated that the PKCs phosphorylate PKD at the T-loop leading to its catalytic activation (31,32). Accordingly, treatment with either Gö6983 or GSK690693 greatly attenuated PKD1 auto-phosphorylation at Ser\textsuperscript{316} induced by either ANG II or serum (Data not shown). Treatment with GSK690693 also inhibited PKD phosphorylation at Ser\textsuperscript{744}, a residue in the activation loop phosphorylated by PKCs (Data not shown). Consequently, we next examined whether the PKDs mediate the effects of mitogenic GPCR agonists on YAP localization and phosphorylation. To test this possibility, we used two structurally unrelated selective inhibitors of PKD activity, CORT0066101 (58) and kb NB 142-70. In previous studies, we demonstrated that these inhibitors block PKD activation and DNA synthesis in IEC-18 cells (36,38,59,60). As shown in Fig. 6 A, exposure of IEC-18 cells to CORT0066101 or kb NB 142-70 prevented YAP redistribution in response to ANGII as effectively as Gö6983. Image analysis verified that the marked YAP translocation from the nucleus to the cytoplasm induced by ANG II was greatly diminished by cell treatment with CORT0066101 (Fig. 6 B, Histogram). Remarkably, CORT0066101 and kb NB 142-70 inhibited YAP phosphorylation at both Ser\textsuperscript{127} and Ser\textsuperscript{397} (Fig. 6 C). In dose-response studies, CORT0066101 and kb NB 142-70 prevented the increase in YAP phosphorylation on Ser\textsuperscript{127} and YAP cytoplasmic accumulation at similar concentrations (Fig. 6 D; quantification in panel E).

The effects of PKD inhibition on YAP localization and phosphorylation were not restricted to ANG II or IEC-18 cells. Treatment with CORT0066101 inhibited rapid cytoplasmic localization and phosphorylation of YAP in response to vasopressin or serum in IEC-18 cells (Data not shown). We also verified that CORT0066101 prevented YAP re-distribution in response to ANG II or vasopressin in IEC-6 cells (Data not shown). These results suggested that PKD signaling is required for GPCR-induced YAP localization and phosphorylation in intestinal epithelial cells.

In order to corroborate that the PKD family plays a key role in the regulation of YAP translocation and phosphorylation, we used small interfering RNA (siRNA)-mediated knockdown of PKD1, PKD2 and PKD3 (Fig. 7). Transfection of a mixture of siRNAs targeting the three PKDs markedly attenuated YAP cytoplasmic localization (Fig. 7 A; image analysis in Fig. 7 B) and phosphorylation at Ser\textsuperscript{127} (Fig. 7 C) in response to GPCR activation. We also determined the effect produced by siRNA-mediated knockdown of the individual PKD isoforms on YAP phosphorylation.
at Ser^{127}. As shown in Fig. 7 D, knockdown of each PKD isoform attenuated the phosphorylation of YAP at Ser^{127}, with a more pronounced inhibitory effect elicited by knockdown of PKD3. These results demonstrated, for the first time, that the PKDs feed into the YAP pathway, as shown by YAP nuclear-cytoplasmic shuttling and phosphorylation in intestinal epithelial cells.

**Stimulation of GPCR/PKD induces YAP localization and phosphorylation via Lats2**

As mentioned previously, GPCR/PKD stimulation induced YAP phosphorylation at highly conserved residues (Ser^{127} and Ser^{397}) located within a consensus sequence phosphorylated by the Hippo core kinases Lats1/2. We therefore determined whether Lats1/2 is activated in response to ANG II via PKD in IEC-18 cells. As shown in Fig. 8 A, ANG II induced a rapid increase in Lats1/2 activity (detectable within 2.5 min), as scored by its phosphorylation at Thr^{1079} (Thr^{1041} in Lats2), residues located in the hydrophobic C-terminal domain targeted by Mst1/2 and critical for Lats1/2 activation (8). In the same lysates, we verified that ANG II induced an even faster activation of PKD (prominent within 1 min) suggesting that PKDs act upstream of Lats in GPCR-stimulated IEC-18 cells. In line with this possibility, the increase in Lats phosphorylation at either Thr^{1079} or Ser^{399} (a residue located within the activation loop of the kinase catalytic domain) induced by ANG II was blunted by treatment with the PKD inhibitors CRT0066101 or kb NB 142-70 (Fig. 8 B). Furthermore, knockdown of Lats2 (but not Lats1) prevented the increase in YAP phosphorylation at Ser^{127} and Ser^{397} as well as extinguished the signals corresponding to Lats phosphorylation at the T loop and hydrophobic C-terminal domain (Fig. 8 C). Furthermore, siRNA-mediated knockdown of Lats2 prevented the rapid nuclear extrusion of YAP induced by stimulation with ANG II (Fig. 8 D; image analysis in Fig. 8 E). These results imply that stimulation of GPCR/PKD induces rapid Lats2 activation leading to YAP phosphorylation and transient cytoplasmic localization in IEC-18 cells. These rapid responses are clearly different from a feedback loop involving transcriptional regulation of YAP/TAZ and Lats2 described in other cell types (61).

**GPCR activation induces expression of Areg and Ctgf through PKD in intestinal epithelial cells.**

The results presented thus far indicate that PKDs play a critical role in mediating the first phase of YAP re-distribution and phosphorylation via Lats2. The changes in YAP localization and phosphorylation were transient, as YAP phosphorylation declined and translocated to the nucleus. We hypothesized that during this second phase of YAP re-localization to the nucleus, YAP couples to TEAD transcription factors and promote YAP/TEAD transcription. To examine the impact of GPCR signaling on the expression YAP/TEAD-regulated genes in intestinal epithelial cells, we determined the expression of Ctgf (Connective tissue growth factor) and Areg (Amphiregulin), which are well-established YAP/TEAD-regulated genes (7). We found that stimulation of IEC-18 cells with ANG II for 1h increased the mRNA levels of Ctgf (3.6 ± 1.4 fold; n= 20) and Areg (14 ± 1.4 fold; n=16) assayed by RT-qPCR. Knockdown of YAP/TAZ with siRNAs averted the increase in the expression of these genes (Fig. 9 A, D), confirming that ANG II induces Ctgf and Areg expression through YAP/TAZ during the second phase of GPCR-mediated YAP/TAZ regulation.

We next determined whether PKDs are implicated in mediating the second phase of GPCR-induced YAP activation. Exposure of intact IEC-18 cells to the PKD family inhibitors CRT0066101 or kb NB 142-70 prevented the increase of Ctgf and Areg mRNA levels in response to ANGII (Fig. 9 B, E). These results suggested that GPCR signaling stimulates YAP/TEAD transcriptional activity in intestinal epithelial cells through PKDs. In agreement with this conclusion, transfection of siRNAs targeting the three PKDs abrogated the increase of Ctgf and Areg mRNA levels in response to GPCR activation. (Fig. 9 C, F). We also determined the inhibitory effect produced by siRNA-mediated knockdown of the individual PKD isoforms on the expression of Ctgf and Areg mRNA levels in response to GPCR activation. Knockdown of each isoform attenuated the increase in Ctgf mRNA, with complete suppression produced by knockdown of all PKDs (Fig. 9 G). Similar results were obtained when the Areg mRNA levels were determined (Data not shown). Collectively, our findings identify a novel function for PKDs in mediating GPCR-induced YAP localization, phosphorylation and transcriptional activity in intestinal epithelial cells.
As indicated above, the changes in YAP localization and phosphorylation in response to GPCR activation were transient, as YAP phosphorylation declined and translocated to the nucleus. Recent studies indicate that Rho activation and actin polymerization stimulate YAP nuclear translocation and consequently, promote YAP/TEAD-regulated gene expression (7). In turn, PKDs can promote Rho activation and actin cytoskeleton organization in a variety of cell types (19,62-64). Indeed, stimulation of IEC-18 cells with ANG II for 1h induced robust actin stress fiber formation (Fig. 10, A, B), a response prevented by either PKD inhibition with CRT0066101 (Fig. 10 A) or siRNA-mediated knockdown of the PKDs (Fig. 10, B). These results implying that PKDs act downstream of ANGII to induce actin remodeling in IEC-18 cells prompted us to determine whether ANG II-induced actin polymerization contributes to the second phase of YAP activation leading to YAP/TEAD-regulated genes in these cells.

We found that treatment of IEC-18 cells with Y16, a novel and potent inhibitor of Rho activation (65), abrogated actin stress fiber formation and prevented the re-entry of YAP into the nucleus (Fig. 10, C). In line with the inhibition of YAP nuclear import, exposure to Y16 blocked the increase in Ctgf and Areg mRNA levels induced by stimulation with ANG II in IEC-18 cells (Fig. 10, D). Exposure of IEC-18 cells to a cell permeable C3 transferase that inactivates RhoA/B/C in intact cells also attenuated the increase in Ctgf and Areg mRNA levels in response to ANG II (Data not shown). In order to substantiate that actin remodeling plays a role in promoting the second phase of YAP activation, we inhibited actin polymerization with latrunculin b, an agent that selectively binds G actin and blocks the formation of F-actin. Treatment of IEC-18 cells with latrunculin b inhibited YAP re-entry into the nucleus (Fig. 10, C) and YAP/TEAD-regulated gene expression (Fig. 10, E). Thus, inhibition of either Rho activation (Y16) or actin polymerization (latrunculin b) prevented YAP/TEAD-regulated gene expression, a hallmark of YAP nuclear entry and activation. We verified that treatment of intact IEC-18 cells with either Y16 or latrunculin b did not block PKD activation in response to ANG II stimulation (Fig. 10, F), indicating that Rho/actin polymerization acts downstream of PKDs in ANG II-stimulated IEC-18 cells. Therefore, our results show that ANGII induces stress fiber formation via PKDs and corroborate that the PKD-dependent changes in cytoskeleton contribute to mediate the second phase of GPCR/PKD-mediated YAP nuclear import and YAP/TEAD activation in IEC-18 cells.

Role of YAP/TEAD in GPCR/PKD-induced mitogenic signaling in intestinal epithelial cells.

In view of our results connecting PKDs with YAP regulation and given our previous results demonstrating a critical role of PKD in GPCR-mediated proliferation in intestinal epithelial cells, we next examined the biological significance of YAP in mediating the proliferative response of intestinal epithelial cells induced via GPCR/PKD activation. A recent high-throughput screen of compounds capable of disrupting the nuclear localization of YAP led to the identification of statins as potent inhibitors of YAP/TAZ/TEAD transcriptional activity (66,67). To determine the role of YAP/TAZ/TEAD in GPCR-induced DNA synthesis, IEC-18 cells were treated with increasing concentrations of cerivastatin prior to stimulation with ANG II. DNA synthesis was measured by assessing [3H]-thymidine incorporation into cellular nucleic acids. Cerivastatin inhibited the stimulation of DNA synthesis induced by ANG II in a dose-dependent manner (Fig. 9, H). Other statins including fluvastatin (3 µM) and simvastatin (10 µM), also abrogated the stimulation of DNA synthesis induced by ANG II (results not shown). Furthermore, siRNA-mediated knockdown of YAP and TAZ markedly inhibited the proliferation of IEC-18 cells (Fig. 9, I). These results imply that the activity of YAP/TAZ is required for the proliferation of intestinal epithelial cells in response to GPCR/PKD activation.

The rapid nuclear exit of YAP is necessary for its function as a transcriptional co-activator

Subsequently, we determined whether the rapid nuclear exit of YAP is necessary for its function as a transcriptional co-activator. Using an available algorithm to predict leucine-rich nuclear export sequence (NES) that potentially mediates nuclear extrusion (68), we identified a NES in YAP within the sequence encompassed by Leu308 to Leu320. Chromosome region maintenance 1 (Crm1; also referred to as exportin1) is the major receptor for the export of proteins out of the nucleus containing a leucine-rich NES.

Leptomycin B (LMB) is an antibiotic that inhibits the formation of complexes consisting of...
Crm1, RanGTP and proteins containing a leucine-rich NES, thereby blocking their nuclear export (69-71). In order to determine whether LMB has any effect on the cellular distribution of YAP, IEC-18 cells were incubated with LMB (10 nM) for 1 h, and then stimulated with ANG II for 30 min. As shown in Fig. 11, A (image analysis in Fig. 11, B), exposure to LMB prevented the nuclear extrusion of YAP induced by ANG II. Consequently, we determined whether treatment with LMB blocks the expression of YAP/TEAD-regulated genes (Ctgf, Areg) induced by ANG II in IEC-18 cells. As shown in Fig. 11 C, LMB markedly inhibited the increase in Areg and Ctgf mRNA levels induced by ANG II. As controls, we verified that LMB did not block the expression of endogenous YAP in response to mitogenic GPCR agonists acting via the AT1 receptor, a GPCR that signals through Gaq/11. This novel pattern of nuclear-cytoplasmic shuttling was also induced by other mitogenic stimuli, including the Gaq/11-coupled receptor agonist vasopressin or serum growth factors in IEC-18 cells. A similar biphasic temporal pattern was also elicited in other intestinal epithelial cells, including rat IEC-6 and human Caco-2. These effects are clearly cell-type dependent, since mitogenic stimuli produced the opposite pattern in HEK293 or PANC-1 cells, in agreement with previous reports using this cell line.

The results presented in Fig. 8 implied that stimulation of GPCR/PKD induces a rapid and transient YAP cytoplasmic localization in IEC-18 cells via Lats2 in IEC-18 cells and the findings in Fig. 11 using LMB indicated that the transient nuclear extrusion of YAP is necessary for its subsequent activation of TEAD-regulated genes in intestinal epithelial cells during the second phase of YAP regulation.

The studies presented here revealed a novel temporal pattern of nuclear-cytoplasmic shuttling of endogenous YAP in response to GPCR activation in untransformed intestinal epithelial cells. Surprisingly, our results identified two phases in the YAP response to mitogenic GPCR agonists in these cells: a rapid but transient localization of YAP to the cytoplasm followed by subsequent re-entry into the nucleus. Importantly, ANG II provoked YAP re-distribution at sub-nanomolar concentrations acting via the AT1 receptor, a GPCR that signals through Gaq/11. This novel pattern of nuclear-cytoplasmic shuttling was also induced by other mitogenic stimuli, including the Gaq/11-coupled receptor agonist vasopressin or serum growth factors in IEC-18 cells. A similar biphasic temporal pattern was also elicited in other intestinal epithelial cells, including rat IEC-6 and human Caco-2. These effects are clearly cell-type dependent, since mitogenic stimuli produced the opposite pattern in HEK293 or PANC-1 cells, in agreement with previous reports using this cell line.

In other cell model systems, the sub-cellular distribution of YAP is controlled by its phosphorylation at Ser127, a highly conserved residue phosphorylated by Lats1/2. The phosphorylation of this residue promotes the shift of YAP from the nucleus to the cytoplasm. Accordingly, we found that ANG II induced a prompt and dose-dependent increase in the phosphorylation of YAP at Ser127. YAP localization and phosphorylation of Ser127 were tightly coupled in IEC-18 cells, as the dose responses of ANG II for eliciting YAP re-localization and phosphorylation were superimposable. In addition to Lats1/2, mammalian NDR1/2 kinases have recently been

**DISCUSSION**

The Hippo/YAP pathway is attracting intense interest as a key regulator of organ-size, tissue regeneration, tumorigenesis and GPCR signaling but the mechanism(s) involved remain incompletely understood. In particular, the precise role of YAP in intestinal epithelial cell proliferation remains incompletely understood, as evidence for both growth-stimulatory and growth-suppressive roles of YAP/TAZ has been presented (14-17).

The results presented here revealed a novel temporal pattern of nuclear-cytoplasmic shuttling of endogenous YAP in response to GPCR activation in untransformed intestinal epithelial cells. Surprisingly, our results identified two phases in the YAP response to mitogenic GPCR agonists in these cells: a rapid but transient localization of YAP to the cytoplasm followed by subsequent re-entry into the nucleus. Importantly, ANG II provoked YAP re-distribution at sub-nanomolar concentrations acting via the AT1 receptor, a GPCR that signals through Gaq/11. This novel pattern of nuclear-cytoplasmic shuttling was also induced by other mitogenic stimuli, including the Gaq/11-coupled receptor agonist vasopressin or serum growth factors in IEC-18 cells. A similar biphasic temporal pattern was also elicited in other intestinal epithelial cells, including rat IEC-6 and human Caco-2. These effects are clearly cell-type dependent, since mitogenic stimuli produced the opposite pattern in HEK293 or PANC-1 cells, in agreement with previous reports using this cell line.

In other cell model systems, the sub-cellular distribution of YAP is controlled by its phosphorylation at Ser127, a highly conserved residue phosphorylated by Lats1/2. The phosphorylation of this residue promotes the shift of YAP from the nucleus to the cytoplasm. Accordingly, we found that ANG II induced a prompt and dose-dependent increase in the phosphorylation of YAP at Ser127. YAP localization and phosphorylation of Ser127 were tightly coupled in IEC-18 cells, as the dose responses of ANG II for eliciting YAP re-localization and phosphorylation were superimposable. In addition to Lats1/2, mammalian NDR1/2 kinases have recently been
proposed to phosphorylate YAP on Ser\textsuperscript{127} in intestinal epithelial cells (48). However, the NDRs did not phosphorylate YAP at Ser\textsuperscript{397} (48), a residue targeted by Lats1/2 (49). We found that stimulation with GPCR agonists or serum induced YAP phosphorylation at Ser\textsuperscript{397}. Indeed, the phosphorylation of YAP at Ser\textsuperscript{127} and Ser\textsuperscript{397} was stimulated by ANG II with identical time-courses and dose-responses. These results suggested that ANG II induces a fast but transient YAP phosphorylation at Ser\textsuperscript{127} and Ser\textsuperscript{397} via Lats1/2 activation within intestinal epithelial IEC-18 cells.

In support of this conclusion, we demonstrated that GPCR activation induced a rapid increase in Lats1/2 activity, as scored by phosphorylation at Thr\textsuperscript{1079/1041}, residues located in the hydrophobic C-terminal domain of Lats1/2 targeted by Mst1/2 and critical for Lats family activation. Importantly, knockdown of Lats2 prevented the increase in the phosphorylation of YAP at Ser\textsuperscript{127} and Ser\textsuperscript{397} and its nuclear extrusion induced by GPCR stimulation. Collectively, our results indicate that stimulation of GPCR induces rapid and transient YAP phosphorylation and cytoplasmic localization through Lats2 in IEC-18 cells.

As a first step to identify upstream pathways that mediate rapid GPCR-induced YAP nuclear-cytoplasmic shuttling and phosphorylation in intestinal epithelial cells, we tested small-molecule inhibitors targeting kinases. Given the role attributed to Akt in Hippo pathway regulation in other cell types (52,53) and the rapid Akt activation in response to ANG II in IEC-18 cells (45), we determined the effect of the Akt inhibitor GSK690693 on YAP re-localization and phosphorylation. We found that GSK690693 blocked the rapid cytoplasmic accumulation and phosphorylation at Ser\textsuperscript{127} and Ser\textsuperscript{397} of YAP induced by ANG II but these inhibitory effects were not replicated by other Akt inhibitors, including GDC-0068 (55) and MK2206 (56). We concluded that GSK690693 potently inhibits YAP cytoplasmic localization and phosphorylation in IEC-18 cells through an Akt-independent pathway.

Although considered a selective Akt inhibitor, GSK690693 is known to inhibit PKA and novel PKCs (57). While suppression of PKA activity within intact IEC-18 cells did not produce any detectable effect on YAP localization or phosphorylation in response to ANG II, treatment with PKC inhibitors greatly attenuated YAP cytoplasmic localization and phosphorylation at both Ser\textsuperscript{127} and Ser\textsuperscript{397}. As indicated above, the AT\textsubscript{1} ANG II receptor acts through G\textsubscript{aq/11} to activate downstream signaling, including stimulation of the isoforms of the phospholipase C (PLC) family which catalyze the hydrolysis of phosphatidylinositol 4,5-biphosphate to produce two second messengers: Ins (1,4,5)P\textsubscript{3}, which triggers the release of Ca\textsuperscript{2+} from internal stores, and DAG, which elicits cellular responses through classic (α, β, γ) and novel (δ, ε, η, θ) isoforms of PKC. In agreement with a recent report (72), the results presented here suggest that PKCs play a role in GPCR-mediated rapid regulation of YAP localization and phosphorylation but the mechanism(s) downstream of PKC remained incompletely understood.

Our previous studies demonstrated that PKDs are rapidly activated through PKC-catalyzed phosphorylation in their kinase activation loop (29-32). Consequently, we hypothesized that YAP localization, phosphorylation and transcriptional activity is regulated by a PKC/PKD axis in intestinal epithelial cells. Here we presented several lines of evidence identifying a novel crosstalk between PKD and YAP: 1) treatment with the structurally unrelated PKD inhibitors CRT0066101 and kb NB 142-70 prevented the rapid cytoplasmic accumulation induced by ANG II in IEC-18 cells; 2) the PKD inhibitors also inhibited phosphorylation of YAP at both Ser\textsuperscript{127} and Ser\textsuperscript{397} and phosphorylation of Lats1/2 at Thr\textsuperscript{1079/1041} and Ser\textsuperscript{909/872}; 3) In dose-response studies, CRT0066101 and kb NB 142-70 prevented ANGII-induced YAP phosphorylation on Ser\textsuperscript{127} and rapid YAP cytoplasmic accumulation at similar concentrations; 4) Knockdown of the PKDs prevented YAP nuclear-cytoplasmic shuttling and phosphorylation at Ser\textsuperscript{127} and Ser\textsuperscript{397} in response to GPCR activation. Thus, our results demonstrate, for the first time, that the PKDs feed into the YAP pathway, as scored by YAP nuclear-cytoplasmic shuttling and phosphorylation in intestinal epithelial cells.

The changes in YAP phosphorylation and localization and Lats activation were transient, as YAP phosphorylation at Ser\textsuperscript{127} and Ser\textsuperscript{397} declined and YAP re-located to the nucleus. Furthermore, PKD-dependent increase in actin stress fiber formation, a characteristic feature of Rho activation, contributed to mediate the second phase
of GPCR/PKD-mediated YAP nuclear import in IEC-18 cells. We hypothesized that during this second phase of nuclear re-entry, YAP couples to TEAD leading to YAP/TEAD-regulated transcription. In agreement with this hypothesis, we found that stimulation of IEC-18 cells with ANG II increased the mRNA levels of the YAP/TAZ/TEAD-regulated genes *Areg* and *Ctgf*, an effect suppressed by knockdown of YAP/TAZ. These results substantiated that ANG II induces *Areg* and *Ctgf* expression through YAP/TAZ during the second phase of GPCR-mediated YAP/TAZ regulation. Based on pharmacological and genetic approaches, we conclude that GPCR signaling stimulates YAP/TEAD transcriptional activity in intestinal epithelial cells through PKDs. Collectively our results identify a novel role for PKDs in regulating both the rapid GPCR-induced YAP cytoplasmic localization and phosphorylation and the subsequent YAP nuclear import and transcriptional activation in intestinal epithelial cells.

Having established biphasic YAP regulation in intestinal epithelial cells via PKDs, we examined whether the second phase of YAP nuclear re-localization and activation contributes to mediate long term biological responses, including re-initiation of DNA synthesis and cell proliferation. Our recent studies with crypt-derived intestinal epithelial cells and PKD1 transgenic mice indicated that PKD1 promotes proliferation and migration of intestinal epithelial cells *in vitro* and *in vivo* (36,38). Interestingly, PKDs and YAP were identified as components of the intestinal stem cell (ISC) signature comprised by 384 unique genes (73). Supporting the notion that YAP/TAZ activation contributes to mediate long-term biological responses, we showed that treatment of IEC-18 cells with cerivastatin, a potent inhibitor of YAP/TAZ activity (66,67), prevented the stimulation of DNA synthesis induced via GPCR/PKD and knockdown of YAP/TAZ suppressed proliferation of intestinal epithelial cells.

It is generally thought that mitogenic stimuli induce rapid YAP dephosphorylation and nuclear localization whereas growth-inhibitory signals promote YAP phosphorylation, cytoplasmic translocation and restricted activity. Our results are of especial significance because they reveal a novel biphasic temporal pattern of nuclear-cytoplasmic shuttling and phosphorylation of YAP in response to GPCR stimulation in confluent and quiescent intestinal epithelial cells. Additional studies demonstrate, for the first time, that the PKD family controls the biphasic localization, phosphorylation and transcriptional activity of YAP in intestinal epithelial cells. In turn, YAP is necessary for the stimulation of the proliferative response of intestinal epithelial cells to GPCR agonists that act via PKD. Interestingly, the rapid nuclear extrusion of YAP is required for the subsequent stimulation of its transcriptional co-activator activity, as shown by the results displayed in Fig. 11, obtained with LMB and knockdown of Lats2.

Taken together, our results suggest a sequential model of YAP activation in response to GPCR stimulation in intestinal epithelial cells (Fig. 11 F). The salient features of this model are as follows: 1) In non-stimulated cells, PKDs and Lats2 are in a state of very low kinase catalytic activity while YAP is localized in the nucleus but not coupled to TEAD transcription factors, as shown by the low expression of *Ctgf* and *Areg*; 2) GPCR stimulation induces rapid PKD activation via PKC-mediated activation loop phosphorylation; 3) Active PKDs promote fast activation of Lats2, as shown by increased phosphorylation in the hydrophobic domain and in the activation loop of this enzyme. In turn, Lats2 mediates YAP phosphorylation at Ser127; 4) phosphorylated YAP is translocated out of the nucleus via a LMB-sensitive, Crm1-mediated mechanism (1st phase); 5) The cytoplasmic phase of YAP translocation is transitory as YAP re-enters into the nucleus when it is dephosphorylated at the Lats2 sites and via GPCR/PKD-induced Rho activation and actin polymerization. YAP can now couple to TEAD thereby promoting the transcription of YAP/TEAD-regulated genes (2nd phase). Thus, we envisage that the rapid but transient GPCR/PKD-induced activation of Lats2 triggers the activation of YAP that after nuclear-cytoplasmic shuttling can act as an effective co-activator of TEAD (Fig. 11 F). While many aspects of this sequence of events are supported by the experimental information presented here, including biochemical, genetic and pharmacological evidence, the elucidation of the precise mechanism by which YAP is activated in the cytoplasm of intestinal epithelial cells requires further experimental work. In conclusion, the discovery of multiple points of interaction between
YAP and PKD signaling identifies a novel crosstalk in epithelial signal transduction and demonstrate, for the first time, that the PKDs feed into the YAP pathway.

**EXPERIMENTAL PROCEDURES**

**Cell Culture**

The non-transformed rat intestinal epithelial IEC-18 and IEC-6 cells (41,42), originated from intestinal crypt cells, were purchased from ATCC. These cells exhibit a number of features similar to normal cells in culture, including a normal rat diploid karyotype, strong density inhibition of growth, lack of growth in soft agar and resemble stem/progenitor cells (74). Cultures of IEC-18, IEC-6 and CaCo-2 cells were maintained as described previously (36,60). Briefly, cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and penicillin-streptomycin, and kept at 37°C in a humidified atmosphere containing 10% CO₂ and 90% air. HEK-293 cells and PANC-1 cells were maintained in culture in DMEM supplemented with 10% FBS, as described previously (51,75). Stock cultures were subcultured every 3-4 days. For experimental purposes, IEC-18 cells were seeded in 35-mm dishes at a density of 2 × 10⁵ cells/dish. Cultures were used 6 days after plating when cell density was 1.5 x 10⁵ cells/cm².

**Immunofluorescence**

Immunofluorescence of IEC18 cells was performed by fixing the cultures with 4% paraformaldehyde followed by permeabilization with 0.4% Triton X-100. After extensive PBS washing, fixed cells were incubated for 2h at 25°C in blocking buffer (BB), consisting of PBS supplemented with 5% bovine serum albumin and penicillin-streptomycin, and kept at 37°C in a humidified atmosphere containing 10% CO₂ and 90% air. HEK-293 cells and PANC-1 cells were maintained in culture in DMEM supplemented with 10% FBS, as described previously (51,75). Stock cultures were subcultured every 3-4 days. For experimental purposes, IEC-18 cells were seeded in 35-mm dishes at a density of 2 × 10⁵ cells/dish. Cultures were used 6 days after plating when cell density was 1.5 x 10⁵ cells/cm².

**Immunoblotting and detection of YAP and PKD1 phosphorylation**

Serum-starved, confluent intestinal epithelial IEC-18 cells were lysed in 2xSDS-polyacrylamide gel electrophoresis (PAGE) sample buffer (20 mM Tris/HCl, pH 6.8, 6% SDS, 2 mM EDTA, 4% 2-mercaptoethanol,10% glycerol) and boiled for 10 min. After SDS-PAGE, proteins were transferred to Immobilon-P membranes. The transfer was carried out at 100 V, 0.4 A at 4°C for 4 h using a Bio-Rad transfer apparatus. The transfer buffer consisted of 200 mM glycine, 25 mM Tris, 0.01% SDS and 20% CH₃OH. For detection of proteins, membranes were blocked using 5% nonfat dried milk in PBS (pH 7.2) and then incubated for at least 2 h with the desired antibodies diluted in PBS containing 0.1% Tween. Primary antibodies were imaged with an epifluorescence Zeiss Axioskop and a Zeiss water objective (Achromat 40/0.75W Carl Zeiss, Inc.). Images were captured as uncompressed 24-bit TIFF files with a cooled (-12°C) single CCD color digital camera (Pursuit, Diagostic Instruments) driven by SPOT version 4.7 software. Alexafluor 488 signals were observed with a HI Q filter set 41001 (Chroma Technology). The selected cells displayed in the appropriate figures were representative of 90% of the population.

**Image Analysis**

Nuclear/cytoplasmic ratios of YAP were determined using the Cell Profiler Software ([www.cellprofiler.org](http://www.cellprofiler.org)). The CellProfiler software was programmed as follows: sequentially, the images of Hoechst 33342 and YAP immunofluorescence at 1024 x 1024 pixel resolution were loaded. The nuclei identified automatically using the Hoechst 33342 signal and then the mean fluorescent intensity of YAP in each nucleus was quantified. The cytoplasmic area of measurement for YAP immunofluorescence was defined by expanding the perimeter of the nuclear outline by 10 pixels, and the mean fluorescent intensity of YAP in each cytoplasmic area was quantified. In all cases, the data was exported to Excel, and the ratio of nuclear/cytoplasmic intensity was calculated for each cell in an image field (180 to 200 cells/field; 6 to 10 fields for each experiment. The results shown are the mean ± SEM of 6 to 10 fields from 1 experiment, a total of 1000 to 2000 cells as indicated in the figure legends and each experiment was repeated at least 3 times.
bound to immunoreactive bands were visualized by enhanced chemiluminescence (ECL) detection with horseradish peroxidase-conjugated anti-mouse, anti-rabbit antibody and a FUJI LAS-4000 Mini Luminescent Image Analyzer.

**Knockdown of PKD family, YAP/TAZ and Lats2 via siRNA transfection**

Silencer Select siRNA duplexes were purchased from Ambion, Life Technologies. The siRNAs were designed to target the mRNA of mouse/rat PKD1, PKD2, PKD3, YAP and TAZ, GenBank mRNA sequences: _Z34524.1_ (PKD1), _BC083592.1_ (PKD2), _BC092663.1_ (PKD3), _DQ186896.2_ (YAP), _BC105631.1_ (TAZ) and _NM_001107267.1(Lats2). The sequences of the siRNAs were as follows; PKD1 sense: CGAUGCAAAUAGACACGAAtt, anti-sense: UUCGCUGUCAUUGUAUCGct PKD2 sense: GUUCUACUGGAGCAAGGAAtt anti-sense: UUCUGUGCCAAGUAGAcc PKD3 sense GCAUUUCACAAGGCAGUAAtt anti-sense: UUAUCUGCCUUGUAAUGCtg, YAP GUUUAACUAACAAACCAUAtt anti-sense UAUGGUUUAAUGUAGUACAt and TAZ GGAUGGACUUCAUUUGGAtt anti-sense UCCAAAAUGAAGUCCAUCCct, Lats2 sense CUCUACGCAGUGGAAACACTG anti-sense UGAGUUUCACCUGCGUAGGga. For siRNA transfection the reverse transfection method was used. The siRNA pool was mixed with Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol and added to 35mm dishes. IEC-18 cells were then plated on top of the siRNA/ Lipofectamine RNAiMAX complex at a density of 2 x 10^5 cells/35 mm dish in DMEM containing 10% FBS. Control transfections were carried out with Silencer Select Negative Control No. 1 (#4390844, Invitrogen, Carlsbad, CA). Three to four days after transfection, cells were used for experiments and subsequent Western blot analysis.

**Immunoprecipitation of YAP.**

Confluent IEC-18 cells were lysed in buffer containing 20 mM Tris-HCl (pH 7.5), 1% Triton, 150 mM NaCl, 1 mM Na_2_EDTA, 1 mM EGTA, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na_3_ VO_4_, 1 μg/ml leupeptin and 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride, hydrochloride (Pefabloc). YAP was immunoprecipitated from the cell extracts with a YAP (H-9) antibody from Santa Cruz Technologies. The immune complexes were recovered using protein-G coupled to agarose.

**Quantitative reverse transcription PCR (qRT-PCR).**

Relative transcript expression levels of _Areg_ and _Ctgf_ were determined by qRT-PCR using a SYBR Green-based method. Briefly, total RNA was extracted from cells by using TRIzol Reagent (Ambion, Life Technologies, Grand Island, NY). Reverse transcription was performed with the iScript reverse transcription supermix (Bio-Rad Laboratories, Hercules, CA), using 1 μg of total input RNA. The synthesized cDNA samples were used as templates for the real-time (RT) PCR analysis. All reactions were performed using the Roche LightCycler480 system and the amplifications were done using the SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad, Hercules, CA). Gene-specific rat oligonucleotide primers for _Areg_ (Unique Assay ID: qRnoCID0001606), _Ctgf_ (Unique Assay ID: qRnoCED0001593), and _Gapdh_ (Unique Assay ID: qRnoCID0057018) were purchased from Bio-Rad, Hercules, CA.

**3H]-Thymidine Incorporation into DNA**

IEC-18 cells were plated and grown in 3.5 cm tissue culture plates for 5 days in DMEM with 2 mM glutamine, 1 mM Na-pyruvate and 10% FBS. To start the experiment, the specified concentration of inhibitor was added to the conditioned medium (4-6 cultures used for each condition). After 18 h of incubation, the cultures were pulse-labeled for 6 h with [3H]-thymidine (0.25 Ci/ml), fixed with 5% trichloroacetic acid and washed twice with ethanol. Acid-insoluble pools corresponding to DNA were solubilized in 0.1 N NaOH with 1% SDS and counted in a liquid scintillation counter.

**Materials**

DMEM, FBS, goat anti-mouse IgG secondary antibody conjugated to Alexa Fluor 488 and Silencer Select siRNAs were obtained from Invitrogen (Carlsbad, CA). Angiotensin II (ANG II), vasopressin, leptomycin B (LMB), Losartan, latrunculin b and Phalloidin-TRITC were obtained from Sigma-Aldrich (St. Louis, MO). The kinase inhibitors kb NB 142-70, CRT0066101, H89, GSK690693, G6983 and GF 109203X, were from R&D Systems (Minneapolis, MN), MK-2206 and GDC-0068 were from Selleckchem (Boston, MA).
The Rho Inhibitor II, Y16 was purchased from EMD Millipore (Billerica, MA). Primary antibodies used were: YAP (H-9, sc-271134 final dilution 1:200 for immunofluorescence, 1:400 for western blotting and 1:100 for immunoprecipitation), PKD C-20 (#sc-639; final dilutions 1:400 for Western Blotting) and GAPDH (sc-365062; final dilution 1:400) from Santa Cruz Biotechnology, Inc. Dallas, Texas), phospho-YAP Ser127 ((D9W2I #13008; final dilution 1:1000) and phospho-YAP Ser397 (D1E7Y #13619; final dilution 1:1000), PKD3 (#5655; final dilutions 1:1000), phospho-Lats1 Ser909 (#9157; final dilution 1:1000), phospho-Lats1 Thr1079 (D57D3 #8654; final dilution 1:1000) all from Cell Signaling Technology (Danvers, MA). The equivalent residues in Lats2 are Ser872 and Thr1041, respectively. Total Lats2 was detected with an antibody from Novus Biologicals (NB200-199; final dilution 1:1000). RT-qPCR reagents were purchased from Bio-Rad (Hercules, CA). All other reagents were of the highest grade available.

Acknowledgments - This work was supported by NIH Grants R01DK100405, P30DK41301 and P01CA163200 and by the Department of Veterans Affair Grant 1I01BX001473 (to ER). Additional funding came from the Ronald S. Hirshberg Endowed Chair of Pancreatic Cancer Research to ER.

Conflict of interest - The authors declare that they have no conflicts of interest with the contents of this article.

Author contributions - ER and JSS are responsible for conception and design of the research; JW, JSS, JVS and SHY performed the experiments; JW, JSS, SHY, and ER analyzed the data; ER and JSS interpreted the results of the experiments; JSS and JW prepared the figures; ER drafted the manuscript; JSS, JW, and ER edited and revised the manuscript; ER approved the final version of the manuscript.
REFERENCES

1. Crosnier, C., Stamataki, D., and Lewis, J. (2006) Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. Nat Rev Genet 7, 349-359
2. Rozengurt, E., and Walsh, J. H. (2001) Gastrin, CCK, signaling, and cancer. Annu Rev Physiol 63, 49-76
3. Rozengurt, E. (2007) Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol 213, 589-602
4. Raufman, J.-P., Samimi, R., Shah, N., Khurana, S., Shant, J., Drachenberg, C., Xie, G., Wess, J., and Cheng, K. (2008) Genetic Ablation of M3 Muscarinic Receptors Attenuates Murine Colon Epithelial Cell Proliferation and Neoplasia. Cancer Res 68, 3573-3578
5. Rey, O., Chang, W., Bikle, D., Rozengurt, N., Young, S. H., and Rozengurt, E. (2012) Negative Cross-talk between Calcium-sensing Receptor and beta-Catenin Signaling Systems in Colonic Epithelium. J Biol Chem 287, 1158-1167
6. Lee, S. J., Leoni, G., Neumann, P. A., Chun, J., Nusrat, A., and Yun, C. C. (2013) Distinct phospholipase C-beta isozymes mediate lysophosphatidic acid receptor 1 effects on intestinal epithelial homeostasis and wound closure. Mol Cell Biol 33, 2016-2028
7. Yu, F.-X., and Guan, K.-L. (2013) The Hippo pathway: regulators and regulations. Genes Dev 27, 355-371
8. Avruch, J., Zhou, D., Fitamant, J., Bardeesy, N., Mou, F., and Barrufet, L. R. (2012) Protein kinases of the Hippo pathway: Regulation and substrates. Semin Cell Dev Biol 23, 770-784
9. Zheng, Y., Wang, W., Liu, B., Deng, H., Uster, E., and Pan, D. (2015) Identification of Happyhour/MAP4K as Alternative Hpo/Mst-like Kinases in the Hippo Kinase Cascade. Dev Cell 34, 642-655
10. Meng, Z., Moroishi, T., Mottier-Pavie, V., Plouffe, S. W., Hansen, C. G., Hong, A. W., Park, H. W., Mo, J.-S., Lu, W., Lu, S., Flores, F., Yu, F.-X., Halder, G., and Guan, K.-L. (2015) MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Nat Commun 6:8357
11. Moroishi, T., Hansen, C. G., and Guan, K.-L. (2015) The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer 15, 73-79
12. Chen, C.-L., Tsukamoto, H., Liu, J.-C., Kashiwabara, C., Feldman, D., Sher, L., Dooley, S., French, S. W., Mishra, L., Petrovic, L., Jeong, J. H., and Machida, K. (2013) Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. J Clin Invest 123, 2832-2849
13. Shanzer, M., Ricardo-Lax, I., Keshet, R., Reuven, N., and Shaul, Y. (2015) The polyomavirus middle T-antigen oncogene activates the Hippo pathway tumor suppressor Lats in a Src-dependent manner. Oncogene 34, 4190-4198
14. Barry, E. R., Morikawa, T., Butler, B. L., Shrestha, K., de la Rosa, R., Yan, K. S., Fuchs, C. S., Magness, S. T., Smits, R., Ogino, S., Kuo, C. J., and Camargo, F. D. (2013) Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 493, 106-110
15. Lee, K.-W., Lee, S. S., Kim, S.-B., Sohn, B. H., Lee, H.-S., Jang, H.-J., Park, Y.-Y., Kopetz, S., Kim, S. S., Oh, S. C., and Lee, J.-S. (2015) Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients. Clin Cancer Res 21, 357-364
16. Imajo, M., Ebisuya, M., and Nishida, E. (2015) Dual role of YAP and TAZ in renewal of the intestinal epithelium. Nat Cell Biol 17, 7-19
17. Hong, A. W., Meng, Z., and Guan, K.-L. (2016) The Hippo pathway in intestinal regeneration and disease. Nat Rev Gastroenterol Hepatol 13, 324-337
18. Rozengurt, E., Rey, O., and Waldron, R. T. (2005) Protein Kinase D Signaling. J Biol Chem 280, 13205-13208
19. Rozengurt, E. (2011) Protein Kinase D Signaling: Multiple Biological Functions in Health and Disease. Physiology 26, 23-33
20. Yuan, J. Z., Slice, L., Walsh, J. H., and Rozengurt, E. (2000) Activation of protein kinase D by signaling through the alpha subunit of the heterotrimeric G protein G(q). *J Biol Chem* **275**, 2157-2164

21. Yuan, J., Slice, L. W., and Rozengurt, E. (2001) Activation of Protein Kinase D by Signaling through Rho and the alpha Subunit of the Heterotrimeric G Protein G13. *J. Biol. Chem.* **276**, 38619-38627

22. Paolucci, L., Sinnett-Smith, J., and Rozengurt, E. (2000) Lysophosphatidic acid rapidly induces protein kinase D activation through a pertussis toxin-sensitive pathway. *Am J Physiol Cell Physiol* **278**, C33-C39

23. Chiu, T., and Rozengurt, E. (2001) PKD in intestinal epithelial cells: rapid activation by phorbol esters, LPA, and angiotensin through PKC. *Am J Physiol Cell Physiol* **280**, C929-942

24. Yuan, J., Slice, L. W., Gu, J., and Rozengurt, E. (2003) Cooperation of Gq, Gi, and G12/13 in protein kinase D activation and phosphorylation induced by lysophosphatidic acid. *J Biol Chem* **278**, 4882-4891.

25. Yuan, J., Rey, O., and Rozengurt, E. (2006) Activation of protein kinase D3 by signaling through Rac and the alpha subunits of the heterotrimeric G proteins G12 and G13. *Cell Signal* **18**, 1051-1062

26. Waldron, R. T., Innamorati, G., Torres-Marquez, M. E., Sinnett-Smith, J., and Rozengurt, E. (2012) Differential PKC-dependent and -independent PKD activation by G protein alpha subunits of the Gq family: selective stimulation of PKD Ser748 autophosphorylation by Galphaq. *Cell Signal* **24**, 914-921

27. Valverde, A. M., Sinnett-Smith, J., Van Lint, J., and Rozengurt, E. (1994) Molecular cloning and characterization of protein kinase D: a target for diacylglycerol and phorbol esters with a distinctive catalytic domain. *Proc Natl Acad Sci USA* **91**, 8572 - 8576

28. Johannes, F. J., Prestle, J., Eis, S., Oberhagemann, P., and Pfizenmaier, K. (1994) PKCu is a novel, atypical member of the protein kinase C family. *J Biol Chem* **269**, 6140-6148

29. Iglesias, T., Waldron, R. T., and Rozengurt, E. (1998) Identification of in vivo phosphorylation sites required for protein kinase D activation. *J Biol Chem* **273**, 27662-27667

30. Waldron, R. T., Rey, O., Iglesias, T., Tugal, T., Cantrell, D., and Rozengurt, E. (2001) Activation Loop Ser744 and Ser748 in Protein Kinase D Are Transphosphorylated in Vivo. *J. Biol. Chem.* **276**, 32606-32615

31. Waldron, R. T., and Rozengurt, E. (2003) Protein kinase C phosphorylates protein kinase D activation loop Ser744 and Ser748 and releases autoinhibition by the pleckstrin homology domain. *J Biol Chem* **278**, 154-163.

32. Rey, O., Reeve, J. R., Jr., Zhukova, E., Sinnett-Smith, J., and Rozengurt, E. (2004) G protein-coupled receptor-mediated phosphorylation of the activation loop of protein kinase D: dependence on plasma membrane translocation and protein kinase Cepsilon. *J Biol Chem* **279**, 34361-34372

33. Matthews, S. A., Rozengurt, E., and Cantrell, D. (1999) Characterization of serine 916 as an in vivo autophosphorylation site for protein kinase D/protein kinase C mu. *J Biol Chem* **274**, 26543-26549

34. Sinnett-Smith, J., Zhukova, E., Hsieh, N., Jiang, X., and Rozengurt, E. (2004) Protein kinase D potentiates DNA synthesis induced by Gq-coupled receptors by increasing the duration of ERK signaling in swiss 3T3 cells. *J Biol Chem* **279**, 16883-16893

35. Sinnett-Smith, J., Jacamo, R., Kui, R., Huang, C., and Rozengurt, E. (2011) Protein kinase D1 mediates stimulation of DNA synthesis and proliferation in intestinal epithelial IEC-18 cells and in mouse intestinal crypts. *J Biol Chem* **286**, 511-520

36. Sinnett-Smith, J., Rozengurt, N., Kui, R., Huang, C., and Rozengurt, E. (2011) Protein kinase D1 mediates stimulation of DNA synthesis and proliferation in intestinal epithelial IEC-18 cells and in mouse intestinal crypts. *J Biol Chem* **286**, 511-520

37. Jacamo, R., Sinnett-Smith, J., Rey, O., Waldron, R. T., and Rozengurt, E. (2008) Sequential protein kinase C (PKC)-dependent and PKC-independent protein kinase D catalytic activation via Gq-
coupled receptors: differential regulation of activation loop Ser(744) and Ser(748) phosphorylation. *J Biol Chem* **283**, 12877-12887

38. Young, S. H., Rozengurt, N., Sinnett-Smith, J., and Rozengurt, E. (2012) Rapid protein kinase D1 signaling promotes migration of intestinal epithelial cells. *Am J Physiol Gastrointest Liver Physiol* **303**, G356-366

39. Chiu, T., Wu, S. S., Santiskulvong, C., Tangkijvanich, P., Yee, H. F., Jr., and Rozengurt, E. (2002) Vasopressin-mediated mitogenic signaling in intestinal epithelial cells. *Am J Physiol Cell Physiol* **282**, C434-450

40. Rey, O., Zhukova, E., Sinnett-Smith, J., and Rozengurt, E. (2003) Vasopressin-induced intracellular redistribution of protein kinase D in intestinal epithelial cells. *J Cell Physiol* **196**, 483-492

41. Quaroni, A., Wands, J., Trelstad, R. L., and Isselbacher, K. J. (1979) Epithelioid cell cultures from rat small intestine. Characterization by morphologic and immunologic criteria. *J. Cell Biol.* **80**, 248-265

42. Quaroni, A., and May, R. J. (1980) Establishment and characterization of intestinal epithelial cell cultures. *Methods Cell Biol* **21B**, 403-427

43. Wu, S. S., Chiu, T., and Rozengurt, E. (2002) ANG II and LPA induce Pyk2 tyrosine phosphorylation in intestinal epithelial cells: role of Ca2+, PKC, and Rho kinase. *Am J Physiol Cell Physiol* **282**, C1432-1444

44. Chiu, T., Santiskulvong, C., and Rozengurt, E. (2005) ANG II stimulates PKC-dependent ERK activation, DNA synthesis, and cell division in intestinal epithelial cells. *Am J Physiol Gastrointest Liver Physiol* **285**, G1-11

45. Chiu, T., Santiskulvong, C., and Rozengurt, E. (2005) EGF receptor transactivation mediates ANG II-stimulated mitogenesis in intestinal epithelial cells through the PI3-kinase/Akt/mTOR/p70S6K1 signaling pathway. *Am J Physiol Gastrointest Liver Physiol* **288**, G182-194

46. Young, S. H., and Rozengurt, E. (2006) Qdot nanocrystal conjugates conjugated to bombesin or ANG II label the cognate G protein-coupled receptor in living cells. *Am J Physiol Cell Physiol* **290**, C728-732

47. Slice, L. W., Chiu, T., and Rozengurt, E. (2005) Angiotensin II and Epidermal Growth Factor Induce Cyclooxygenase-2 Expression in Intestinal Epithelial Cells through Small GTPases Using Distinct Signaling Pathways. *J Biol Chem* **280**, 1582-1593

48. Zhang, L., Tang, F., Terracciano, L., Hynx, D., Kohler, R., Bichet, S., Hess, D., Cron, P., Hemmings, Brian A., Hergovich, A., and Schmitz-Rohmer, D. (2015) NDR Functions as a Physiological YAP1 Kinase in the Intestinal Epithelium. *Curr Biol* **25**, 296-305

49. GC0068 Zhao, B., Li, L., Tumaneng, K., Wang, C.-Y., and Guan, K.-L. (2010) A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCFβ-TRCP. *Genes Dev* **24**, 72-85

50. Guha, S., Rey, O., and Rozengurt, E. (2002) Neurotensin Induces Protein Kinase C-dependent Protein Kinase D Activation and DNA Synthesis in Human Pancreatic Carcinoma Cell Line PANC-1. *Cancer Res* **62**, 1632-1640

51. Soares, H. P., Ni, Y., Kisfalvi, K., Sinnett-Smith, J., and Rozengurt, E. (2013) Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells. *PLoS One* **8**, e57289

52. Kim, D., Shu, S., Coppola, M. D., Kaneko, S., Yuan, Z.-q., and Cheng, J. Q. (2010) Regulation of Proapoptotic Mammalian ste20–Like Kinase MST2 by the IGF1-Akt Pathway. *PLoS ONE* **5**, e9616

53. Collak, F. K., Yagiz, K., Luthringer, D. J., Erkaya, B., and Cinar, B. (2012) Threonine-120 Phosphorylation Regulated by Phosphoinositide-3-Kinase/Akt and Mammalian Target of Rapamycin Pathway Signaling Limits the Antitumor Activity of Mammalian Sterile 20-Like Kinase 1. *J Biol Chem* **287**, 23698-23709

54. Rhodes, N., Heerding, D. A., Duckett, D. R., Eberwein, D. J., Knick, V. B., Lansing, T. J., McConnell, R. T., Gilmer, T. M., Zhang, S.-Y., Robell, K., Kahana, J. A., Geske, R. S.,
Kleymenova, E. V., Choudhry, A. E., Lai, Z., Leber, J. D., Minthorn, E. A., Strum, S. L., Wood, E. R., Huang, P. S., Copeland, R. A., and Kumar, R. (2008) Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity. *Cancer Res* **68**, 2366-2374

55. Blake, J. F., Xu, R., Bencsik, J. R., Xiao, D., Kallan, N. C., Schlachter, S., Mitchell, I. S., Spencer, K. L., Banka, A. L., Wallace, E. M., Glover, S. L., Martinson, M., Woessner, R. D., Vigers, G. P. A., Brandhuber, B. J., Liang, J., Safina, B. S., Li, J., Zhang, B., Chabot, C., Do, S., Lee, L., Oeh, J., Sampath, D., Lee, B. B., Lin, K., Liederer, B. M., and Skelton, N. J. (2012) Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors. *J Med Chem* **55**, 8110-8127

56. Hirai, H., Sootome, H., Nakatsu, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B.-S., and Kotani, H. (2010) MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo. *Mol Cancer Ther* **9**, 1956-1967

57. Davis, M. I., Hunt, J. P., Herrgard, S., Cicero, P., Wodicka, L. M., Pallass, G., Hocker, M., Treiber, D. K., and Zarrinkar, P. P. (2011) Comprehensive analysis of kinase inhibitor selectivity. *Nat Biotech* **29**, 1046-1051

58. Harikumar, K. B., Kunnumakkara, A. B., Ochi, N., Tong, Z., Deorukhkar, A., Sun, B., Kelland, L., Jamieson, S., Sutherland, R., Raynham, T., Charles, M., Bagherazadeh, A., Foxton, C., Boakes, A., Farooq, M., Maru, D., Diagaradjan, P., Matsuo, Y., Sinnett-Smith, J., Gelovani, J., Krishnan, S., Aggarwal, B. B., Rong, E., Ireson, C. R., and Guha, S. (2010) A Novel Small-Molecule Inhibitor of Protein Kinase D Blocks Pancreatic Cancer Growth In vitro and In vivo. *Mol Cancer Ther* **9**, 1136-1146

59. Sinnett-Smith, J., Ni, Y., Wang, J., Ming, M., Young, S. H., and Rozengurt, E. (2014) Protein kinase D1 mediates class IIa histone deacetylase phosphorylation and nuclear extrusion in intestinal epithelial cells: role in mitogenic signaling. *Am J Physiol Cell Physiol* **306**, C961-C971

60. Ni, Y., Sinnett-Smith, J., Young, S. H., and Rozengurt, E. (2013) PKD1 Mediates Negative Feedback of PI3K/Akt Activation in Response to G Protein-Coupled Receptors. *PLoS One* **8**, e73149

61. Scholz, R.-P., Gustafsson, J. O. R., Hoffmann, P., Jaiswal, M., Ahmadian, M. R., Eisler, S. A., Erlmann, P., Schmid, S., Haussers, A., and Olayioye, M. A. (2011) The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation. *Exp Cell Res* **317**, 496-503

62. Scholz, R.-P., Gustafsson, J. O. R., Hoffmann, P., Jaiswal, M., Ahmadian, M. R., Eisler, S. A., Erlmann, P., Schmid, S., Haussers, A., and Olayioye, M. A. (2011) The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation. *Exp Cell Res* **317**, 496-503

63. Pusapati, G. V., Eiseler, T., Rykx, A., Vandoninck, S., Derua, R., Waelkens, E., Van Lint, J., von Wichert, G., and Seufferlein, T. (2012) Protein Kinase D Regulates RhoA Activity via Rhotekin Phosphorylation. *J Biol Chem* **287**, 9473-9483

64. Shang, X., Marchioni, F., Evelyn, C. R., Sipes, N., Zhou, X., Seibel, W., Wortman, M., and Zheng, Y. (2013) Small-molecule inhibitors targeting G-protein–coupled Rho guanine nucleotide exchange factors. *Proc Natl Acad Sci USA* **110**, 3155-3160

65. Sorrentino, G., Ruggeri, N., Specchia, V., Cordenonsi, M., Mano, M., Dupont, S., Manfrin, A., Ingallina, E., Sommaggio, R., Piazza, S., Rosato, A., Piccolo, S., and Del Sal, G. (2014) Metabolic control of YAP and TAZ by the mevalonate pathway. *Nat Cell Biol* **16**, 357-366

66. Wang, Z., Wu, Y., Wang, H., Zhang, Y., Mei, L., Fang, X., Zhang, X., Zhang, F., Chen, H., Liu, Y., Jiang, Y., Sun, S., Zheng, Y., Li, N., and Huang, L. (2014) Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. *Proc Natl Acad Sci USA* **111**, E89-E98
FIGURE LEGENDS

Figure 1. ANGII induces rapid YAP cytoplasmic localization in intestinal epithelial IEC-18 cells.
A, Confluent and quiescent cultures of IEC-18 cells were stimulated without (-) or with 10 nM ANG II for the indicated times. The cultures were then washed, fixed with 4% paraformaldehyde and stained with an antibody that detects total YAP and with Hoechst 33342 to visualize the cell nuclei. B, Quantification of the images shown in panel A was determined with the CellProfiler software, as described in “Experimental Procedures”. The plot shown represents the mean nuclear/cytoplasmic ratios of YAP immunofluorescence ± SEM n=8 fields (~1,400 cells were analyzed for each time point). Similar results were obtained in 3 independent experiments. C, The histogram represents the distribution of control and ANG II-stimulated cells (at 30 min) as a function of their nuclear/cytoplasmic ratio of YAP immunofluorescence based on the analysis of ~1,700 cells from one experiment. Similar results were obtained in 10 independent experiments. D, Confluent cultures of IEC-18 cells were stimulated without (-) or with either 10% FBS (FBS) or 50 nM vasopressin (VP) for 30 min. The cultures were then washed, fixed with 4% paraformaldehyde and stained with an antibody that detects total YAP and with Hoechst 33342 to visualize the cell nucleus. Similar results were obtained in 3 independent experiments.

Figure 2. ANGII induces YAP cytoplasmic localization in a dose dependent manner via the AT1 receptor in IEC-18 cells.
A, Confluent cultures of IEC-18 cells were stimulated with ANG II at the indicated concentrations for 30 min. The cultures were then washed, fixed with 4% paraformaldehyde and stained with an antibody that detects total YAP and with Hoechst 33342 to visualize the cell nuclei. B, Quantification of nuclear/cytoplasmic ratio of YAP immunofluorescence shown in panel A was determined with the CellProfiler software as described in “Experimental procedures”. The plot shown are the mean ratios ± SEM n=7 fields (~1,250 cells were analyzed for each concentration of ANG II). Similar results were obtained in a separate experiment. C, Confluent cultures of IEC-18 cells were incubated without (0) or with the selective ANG II type 1 (AT1) receptor antagonist losartan (Los) at 10µM for 30 min prior to stimulation with 10nM ANGII for 30 min. The cultures were then washed, fixed with 4% paraformaldehyde and stained...
with an antibody that detects total YAP and with Hoechst 33342 to visualize the cell nuclei. Similar results were obtained in 3 independent experiments.

**Figure 3. ANGII induces rapid increase in the phosphorylation of YAP at Ser\(^{127}\) and Ser\(^{397}\) in IEC-18 cells.**

A and B, Confluent cultures of IEC-18 cells were incubated without (-) or with ANGII (ANG) for the indicated times (A) or concentrations (B). Cultures were then lysed with 2×SDS–PAGE sample buffer and analyzed by immunoblotting with antibodies that detect YAP phosphorylated at Ser\(^{127}\) and Ser\(^{397}\). Immunoblotting for total YAP and GAPDH were also included. C, Quantification of total YAP phosphorylated at Ser\(^{127}\) and Ser\(^{397}\) was performed using Multi Gauge V3.0. The results represent the mean ± S.E.; n = 3 and are expressed as percentage of the maximal level of YAP phosphorylated at Ser\(^{127}\) and Ser\(^{397}\). Similar results were obtained in 3 independent experiments. D, Confluent cultures of IEC-18 cells were stimulated with 10 nM ANGII for 30 min. Then, the cells were lysed and YAP immunoprecipitates (IP. YAP) were analyzed by western blotting (W.B.) with YAP Ser\(^{127}\) and Ser\(^{397}\). E, Cultures of IEC-18 cells were transfected with non-targeting siRNA (N. Targ) or with siRNAs targeting YAP for 4 days. Then, the cultures were then stimulated with 10 nM ANGII for 30 min. Cells were lysed with 2×SDS–PAGE sample buffer and analyzed by immunoblotting antibodies that detect YAP phosphorylated at Ser\(^{127}\) and Ser\(^{397}\), total YAP and GAPDH. Similar results were obtained in 4 independent experiments.

**Figure 4. GPCR agonists and serum induce cytoplasmic localization and phosphorylation of YAP in IEC-6 and Caco-2 intestinal epithelial cells.**

A, B, C and D (upper), Confluent cultures of IEC-6 (A), Caco-2 (B) HEK293 (C) and PANC-1 (D) cells were stimulated with 10 nM ANG II (A), 10% FBS (B, C) or 10 nM neurotensin, NT, (D), as indicated. The cultures were then washed, fixed with 4% paraformaldehyde and stained with an antibody that detects total YAP and with Hoechst 33342 to visualize the cell nuclei. A, B, C and D (lower), Confluent cultures of IEC-6 (A), Caco-2 (B) and HEK293 (C) and PANC-1 (D) cells were stimulated with 10 nM ANG II (A), 10% FBS or 10µM LPA (B, C) or 10 nM neurotensin, NT, (D) for the indicated times. Cultures were then lysed with 2×SDS–PAGE sample buffer and analyzed by immunoblotting antibodies that detect YAP phosphorylated at Ser\(^{127}\) and total YAP. Similar results were obtained in at least 2 independent experiments.

**Figure 5. ANGII induces cytoplasmic localization and phosphorylation of YAP through an Akt-independent but PKC-dependent pathway in IEC-18 cells.**

A, Confluent cultures of IEC-18 cells were incubated in the absence (0) or presence of 2.5 µM GSK690693 (GSK), 2.5 µM GDC-0068 (GDC) or 5 µM MK2206 (MK) for 1 h prior to stimulation of the cells without (-) or with 10 nM ANG II for 30min. The cultures were then washed, fixed with 4% paraformaldehyde and stained with an antibody that detects total YAP and with Hoechst 33342 to visualize the cell nuclei. B, Quantification of the nuclear/cytoplasmic ratio of YAP immunofluorescence shown in panel A was determined with the CellProfiler software. The bars shown are the mean nuclear/cytoplasmic ratio ± SEM n= 6 fields (~1,200 cells were analyzed for each condition). Similar results were obtained in 3 independent experiments. C, Confluent cultures of IEC-18 cells were incubated in the absence (0) or presence of 2.5 µM GSK690693 (GSK), 2.5 µM GDC-0068 (GDC) or 5 µM MK2206 (MK) for 1 h prior to stimulation of the cells without (-) or with 10 nM ANG II for 30 min. Cells were then lysed with 2×SDS–PAGE sample buffer and analyzed by immunoblotting with antibodies that detect YAP phosphorylated at either Ser\(^{127}\) or Ser\(^{397}\), PRAS40 phosphorylated at Thr\(^{246}\) and total YAP and GAPDH. Similar results were obtained in 3 independent experiments. D, Confluent cultures of IEC-18 cells were incubated in the absence (0) or presence of 2.5 µM GSK690693 (GSK), 5 µM G66983 (Go), 5 µM GFI or 10 µM H89 for 1 h prior to stimulation of the cells without (-) or with 10 nM ANG II for 30 min. The cultures were then washed, fixed with 4% paraformaldehyde and stained with an antibody that detects total YAP and with Hoechst 33342 to visualize the cell nuclei. E, Quantification of the nuclear/cytoplasmic ratio of YAP immunofluorescence shown in panel D was determined with the CellProfiler software. The bars shown are the mean nuclear/cytoplasmic ratios ± SEM n= 6 fields (~1,100 cells were analyzed for each condition). Similar
results were obtained in 4 independent experiments. F, Confluent cultures of IEC-18 cells were incubated in the absence (0) or presence of 2.5 µM GSK690693 (GSK), 5 µM Gö6983 (Go), 5 µM GFI or 10 µM H89 for 1 h prior to stimulation of the cells without (-) or with 10 nM ANG II for 30 min. Cells were then lysed with 2×SDS–PAGE sample buffer and analyzed by immunoblotting antibodies that detect YAP phosphorylated at Ser127 and Ser397 and total YAP. Similar results were obtained in 3 independent experiments.

Figure 6. PKD family inhibitors prevent transient YAP translocation and phosphorylation in response to ANG II in IEC-18 cells.
A, Confluent cultures of IEC-18 cells were incubated in the absence (0) or presence of 5 µM Gö6983, 3.5 µM kbNB 142-70 (kb) or 2.5 µM CRT0066101 (CRT) for 1 h prior to stimulation of the cells without (-) or with 10 nM ANG II for 30 min. The cultures were then washed, fixed with 4% paraformaldehyde and stained with an antibody that detects total YAP and with Hoechst 33342 to visualize the cell nuclei. B, Quantification of the nuclear/cytoplasmic ratio of YAP immunofluorescence was determined using CellProfiler. The bars shown represent, control (open bars), ANG II (red bars), ANG II + CRT (blue bars) and are the nuclear/cytoplasmic ratios from ~1,000 cells from 1 experiment. Similar results were obtained in 6 independent experiments. C, Confluent cultures of IEC-18 cells were incubated in the absence (0) or presence of 5 µM Gö6983 (Go), 3.5 µM kbNB 142-70 (kb) or 2.5 µM CRT0066101 (CRT) for 1 h prior to stimulation of the cells without (-) or with 10 nM ANG II for 30 min. Cells were then lysed with 2×SDS–PAGE sample buffer and analyzed by immunoblotting antibodies that detect YAP phosphorylated at Ser127 and Ser397, PKD1 phosphorylated at Ser916, PKD2/3 and YAP and GAPDH. Similar results were obtained in 6 independent experiments. D and E, Confluent cultures of IEC-18 cells were incubated in the absence (0) or presence of increasing concentrations of either CRT0066101 (closed squares, in E) or kb NB 142–70 (open squares in E) for 1 h prior to stimulation of the cells without (-) or with 10 nM ANG II for 30 min. Cells were then lysed with 2×SDS–PAGE sample buffer and analyzed by immunoblotting antibodies that detect YAP phosphorylated at Ser127, total YAP and GAPDH. Quantification YAP Ser127 phosphorylation (shown in panel E) was performed using Multi Gauge V3.0. The results represent the mean ± S.E.; n = 3 and are expressed as percentage of the maximum level of YAP Ser127. E, Confluent cultures of IEC-18 cells were incubated in the absence (grey circle) or in the presence of increasing concentrations of CRT0066101 (closed circles) or kbNB 142-70 (open circles) for 1 h indicated prior to stimulation of the cells without or with 10 nM ANG II for 30 min. The cultures were then washed, fixed with 4% paraformaldehyde and stained with an antibody that detects total YAP and with Hoechst 33342 to visualize the cell nuclei and analyzed with the CellProfiler software. The results shown are the nuclear/cytoplasmic ratio of YAP immunofluorescence ± SEM; ~700 cells were analyzed at each concentration of CRT0066101 (closed circles) or kbNB 142-70 (open circles). Similar results were obtained in 2 independent experiments.

Figure 7. Knockdown of PKD family expression prevents YAP translocation and phosphorylation in response to ANG II in IEC18 cells.
A, Cultures of IEC-18 cells were transfected with non-targeting siRNA (N. Targ) or with a mixture of siRNAs targeting PKD1, PKD2 and PKD3 (siPKD) for 4 days. Then, the cultures were stimulated with 10 nM ANGII for 30 min, washed, fixed with 4% paraformaldehyde and stained with an antibody that detects total YAP and with Hoechst 33342 to visualize the cell nuclei. B, Quantification of the nuclear/cytoplasmic ratio of YAP immunofluorescence shown in panel A was determined with the CellProfiler software. The bars shown are the mean nuclear/cytoplasmic ratio ± SEM; n = 10 fields (~1,800 cells were analyzed for each condition). Similar results were obtained in 4 independent experiments. C, Cultures of IEC-18 cells were transfected with non-targeting siRNA (N. Targ) or with a mixture of siRNAs targeting PKD1, PKD2 and PKD3 (siPKD) for 4 days. Then, the cultures were stimulated with 10 nM ANGII for 30 min, lysed with 2×SDS–PAGE sample buffer and analyzed by immunoblotting with antibodies that detect YAP phosphorylated at Ser127 or Ser397 and total YAP, PKD1/2 (PKD C-20), PKD3 and GAPDH. Similar results were obtained in 4 independent experiments. D, Cultures of IEC-18 cells were transfected with non-
targeting siRNA (N. T.) or with siRNAs targeting individual PKD1, PKD2 or PKD3 and with a mixture of siRNAs targeting the three isoforms (siPKD) for 4 days. Then, the cultures were stimulated with 10 nM ANG II for 30 min. Cells were then lysed with 2×SDS–PAGE sample buffer and analyzed by immunoblotting antibodies that detect YAP phosphorylated at Ser127. Quantification of YAP phosphorylated at Ser127 was performed using Multi Gauge V3.0. The results represent the mean ± S.E.; n = 4 and are expressed as percentage of the maximal level of YAP phosphorylated at Ser127. Similar results were obtained in 4 independent experiments.

Figure 8. GPCR/PKD induces a transient activation of Lats leading to YAP localization and phosphorylation in IEC18 cells.
A, Confluent cultures of IEC-18 cells were incubated without (0) or with 10 nM ANGII for the indicated times. Cultures were then lysed with 2×SDS–PAGE sample buffer and analyzed by immunoblotting antibodies that detect Lats1/2 phosphorylated at Thr1079/1041, PKD1 phosphorylated at Ser916, PKDs phosphorylated at Ser744, total PKD1/2 (PKD C-20), total Lats2 and GAPDH. Similar results were obtained in 2 independent experiments. B, Confluent cultures of IEC-18 cells were incubated in the absence (0) or presence of 2.5 µM CRT0066101 (CRT) or 3.5 µM kbNB 142-70 (kb) for 1 h prior to stimulation of the cells without or with 10 nM ANG II for 30 min. Cells were then lysed with 2×SDS–PAGE sample buffer and analyzed by immunoblotting antibodies that detect Lats1/2 phosphorylated at Thr1079/1041 and Ser909/872, PKD1 phosphorylated at Ser916, PKDs phosphorylated at Ser744, total PKD1/2 (PKD C-20), total Lats2 and GAPDH. Similar results were obtained in 2 independent experiments. C, Cultures of IEC-18 cells were transfected with non-targeting siRNA (N. Targ.) or with siRNAs targeting Lats2 for 4 days. Then, the cultures were stimulated with 10 nM ANGII for 30 min, lysed with 2×SDS–PAGE sample buffer and analyzed by immunoblotting with antibodies that detect YAP phosphorylated at Ser127 and Ser397, total YAP, Lats1/2 phosphorylated at Thr1079/1041 and Ser909/872, total Lats2 and GAPDH. Note that siRNA-mediated knockdown of Lats2 extinguished the signals detected with the phospho-Lats1/2 antibodies, implying that Lats2 is the predominant Lats kinase expressed endogenously by IEC-18 cells. Similar results were obtained in 3 independent experiments. D, Cultures of IEC-18 cells were transfected with non-targeting siRNA (N. Targ) or with siRNAs targeting Lats2 for 4 days. The cultures were stimulated with 10 nM ANGII for 30 min. Then cultures were washed, fixed with 4% paraformaldehyde and stained with an antibody that detects total YAP and with Hoechst 33342 to visualize the cell nuclei. E, Quantification of the nuclear/cytoplasmic ratio of YAP immunofluorescence shown in panel D was determined with the CellProfiler software. The bars shown are the mean nuclear/cytoplasmic ratio ± SEM n= 5 fields (~900 cells). Similar results were obtained in 3 independent experiments.

Figure 9. ANG II induces increased expression of Areg and Ctgf through PKDs in IEC18 cells.
A and D, Cultures of IEC-18 cells were transfected with non-targeting siRNA (N. T) or with siRNAs targeting YAP and TAZ (siYAP/TAZ). Then, the cultures were stimulated with 10 nM ANG II for 1 h. RNA was isolated and the relative levels (n=3) of Ctgf (A) and Areg (D) mRNAs compared with Gapdh mRNA were measured by RT-qPCR. Data were presented as mean ± SEM. B and E, Confluent cultures of IEC-18 cells were incubated in the in the absence (0) or presence of either 2.5 µM CRT0066101 (CRT) or 3.5 µM kb NB 142–70 (kb) for 1 h prior to stimulation of the cells without or with 10 nM ANG II for 1 h, as indicated. RNA was isolated and the relative levels (n=3) of Ctgf (B) or Areg (E) mRNA compared with Gapdh mRNA was measured by RT-qPCR. Data are presented as mean ± SEM. C and F, Cultures of IEC-18 cells were transfected with non-targeting siRNA (N. T) or with a mixture of siRNAs targeting PKD1, PKD2 and PKD3 (siPKD). Then, the cultures were stimulated with 10 nM ANGII for 1 h. RNA was isolated and the relative levels (n=3) of Ctgf (C) or Areg (F) mRNAs compared with Gapdh mRNA were measured by RT-qPCR. Data are presented as mean ± SEM. C and F, Cultures of IEC-18 cells were transfected with non-targeting siRNA (N. T.) or with either siRNAs targeting the individual PKDs i.e. PKD1, PKD2 or PKD3 or a mixture of siRNAs to PKD1, PKD2 and PKD3 (siPKD). Then, the cultures were stimulated with 10 nM ANG II
for 1 h. RNA was isolated and the relative levels (n=6) of Ctgf mRNAs compared with Gapdh mRNA were measured by RT-qPCR. Data were presented as mean ± SEM. Similar results were obtained in 2 independent experiments. Confluent cultures of IEC-18 cells were incubated in the absence or presence for 24 h with the indicated concentrations of cerivastatin in conditioned medium prior to stimulation with 10 nM ANG II for 18 hr and then pulse-labeled with [3H]-thymidine (0.25 µCi/ml) for 6 h. The radioactivity incorporated into acid-insoluble pools was measured in a scintillation counter. Similar results were obtained in 4 independent experiments. Cultures of IEC-18 cells were transfected with non-targeting siRNA (N. Targ.) or with siRNAs targeting YAP and TAZ (siYAP/TAZ). Cell numbers were determined from 3 plates per condition each day for 4 days. Similar results were obtained in 2 independent experiments.

Figure 10. GPCR/PKD-mediates YAP re-entry into the nucleus through Rho and actin remodeling. A, Confluent and quiescent cultures of IEC-18 cells were incubated in the absence (0) or presence of 2.5 µM CRT0066101 (CRT) for 1 h prior to stimulation without (-) or with 10 nM ANG II for 1 h. The cultures were then washed, fixed with 4% paraformaldehyde and stained with TRITC-conjugated phalloidin. B, Cultures of IEC-18 cells were transfected with non-targeting siRNA (N. Targ) or with a mixture of siRNAs targeting PKD1, PKD2 and PKD3 (siPKD) for 4 days. Then, the cultures were stimulated with 10 nM ANGII for 1 h, washed, fixed with 4% paraformaldehyde and stained with TRITC-conjugated phalloidin. C, Confluent cultures of IEC-18 cells were incubated in the absence (0) or presence of 20 µM Y16 or 2.5 µM latrunculin B (Ltb) for 1 h prior to stimulation of the cells without (-) or with 10 nM ANG II for 1 h. The cultures were then washed, fixed with 4% paraformaldehyde and stained with an antibody that detects total YAP, Hoechst 33342 to visualize the cell nuclei and TRITC-conjugated phalloidin. D, Confluent cultures of IEC-18 cells were incubated in the absence (0) or presence of 20 µM Y16 for 1 h prior to stimulation of the cells without or with 10 nM ANG II for 1 h, as indicated. RNA was isolated and the relative levels (n=3) of Ctgf and Areg mRNA compared with Gapdh mRNA was measured by RT-qPCR. Data are presented as mean ± SEM. Similar results were obtained in 3 independent experiments. E, Confluent cultures of IEC-18 cells were incubated in the absence (0) or presence of 2.5 µM latrunculin B for 1 h prior to stimulation of the cells without or with 10 nM ANG II for 1 h, as indicated. RNA was isolated and the relative levels (n=3) of Ctgf and Areg mRNA compared with Gapdh mRNA was measured by RT-qPCR. Data are presented as mean ± SEM. Similar results were obtained in 3 independent experiments. F, Confluent cultures of IEC-18 cells were incubated in the absence (0) or presence of 2.5 µM CRT0066101 (CRT), 20 µM Y16 or 2.5 µM latrunculin B (Ltb) for 1 h prior to stimulation of the cells without (-) or with 10 nM ANG II for 1 h. Cells were then lysed with 2×SDS–PAGE sample buffer and analyzed by immunoblotting antibodies that detect PKD1 phosphorylated at Ser916, total PKD1/2 (PKD C-20) and GAPDH. Similar results were obtained in 3 independent experiments.

Figure 11. Leptomycin B prevents the nuclear extrusion of YAP and inhibits the expression Ctgf and Areg induced by ANG II in IEC-18 cells A, Confluent cultures of IEC-18 cells were incubated in the absence (0) or presence of 10 nM leptomycin B (LMB) for 1 h prior to stimulation of the cells without (-) or with 10 nM ANG II for 30 min. The cultures were then washed, fixed with 4% paraformaldehyde and stained with an antibody that detects total YAP and with Hoechst 33342 to visualize the cell nuclei. B, Quantification of the nuclear/cytoplasmic ratio of YAP immunofluorescence shown in panel A was determined with the CellProfiler software. The bars shown are the mean nuclear/cytoplasmic ratio ± SEM; n= 5 (~900 cells for each condition). Similar results were obtained in 2 independent experiments. C, Confluent cultures of IEC-18 cells were incubated in the absence (0) or presence of 10 nM LMB for 1 h prior to stimulation of the cells without or with 10 nM ANG II for 1 h, as indicated. RNA was isolated and the relative levels (n=3) of Areg and Ctgf mRNA compared with Gapdh mRNA was measured by RT-qPCR. Data are presented as mean ± SEM. Similar results were obtained in 3 independent experiments. D, Confluent cultures of IEC-18 cells were incubated in the absence (0) or presence of 10 nM LMB for 1 h prior to stimulation of the cells without (-) or with 10 nM ANG II for 30 min, as indicated. Cells were then lysed with 2×SDS–PAGE sample buffer and analyzed by immunoblotting with antibodies that detect YAP phosphorylated at Ser127 and Ser397, PKD1 phosphorylated...
Protein kinase D regulation of YAP signaling

PKDs phosphorylated at Ser916, PKDs phosphorylated at Ser744 and total PKD1/2 (PKD C-20), PKD3, YAP and GAPDH. Similar results were obtained in 2 independent experiments.

E, Cultures of IEC-18 cells were transfected with non-targeting siRNA (N. Targ.) or with siRNAs targeting Lats2 for 4 days. Then, the cultures were stimulated with 10 nM ANG II for 1 h. RNA was isolated and the relative levels (n=3) of Ctgf and Areg mRNAs compared with Gapdh mRNA were measured by RT-qPCR. Similar results were obtained in 2 independent experiments. Data were presented as mean ± SEM.

F, Scheme representing a sequential model of YAP/TEAD activation in response to GPCR stimulation in intestinal epithelial cells. In non-stimulated cells, PKDs and Lats2 are in a state of very low kinase catalytic activity while YAP is localized in the nucleus but not coupled to TEAD transcription factors, as shown by the low expression of Ctgf and Areg mRNAs. GPCR stimulation induces rapid PKC/PKD activation leading to fast activation of Lats2. In turn, Lats2 mediates YAP phosphorylation at Ser127 which is transported out of the nucleus via Crm1 (1st phase). The cytoplasmic phase of YAP translocation is transitory as it re-enters the nucleus when it is dephosphorylated and GPCR/PKD activation induces Rho activation and actin stress fiber formation (Actin Pol). YAP can now couple to TEAD thereby promoting the transcription of YAP/TEAD-regulated genes (2nd phase). The states of YAP are indicated in the scheme. The superscripts denote localization (N, nuclear; Cyt, cytosolic) whereas the subscripts indicate activity (U, uncoupled from TEAD; C, coupled to TEAD). Thus, we propose: rapid GPCR-PKC/PKD-Lats2 activation leading to Crm1-mediated YAP nuclear exit followed by gradual PKD-Rho/actin polymerization leading to YAP nuclear re-entry and YAP/TEAD-regulated gene expression during the gradual 2nd phase.
A

| Time, min | ANGII | ANGII | ANGII | ANGII |
|-----------|-------|-------|-------|-------|
| 0         |       |       |       |       |
| 15        |       |       |       |       |
| 30        |       |       |       |       |
| 60        |       |       |       |       |
| 120       |       |       |       |       |

YAP

Hoechst

- ANGII - ANGII - ANGII - ANGII

B

Figure 1

YAP

Hoechst

- FBS VP

- FBS VP

Figure 1
Figure 2

A

| ANGII, nM | 0   | 0.1 | 0.4 | 0.8 | 1.6 |
|-----------|-----|-----|-----|-----|-----|
| YAP       |     |     |     |     |     |
| Hoechst   |     |     |     |     |     |

B

Ratio of Mean Intensity Nuclear/Cytoplasmic

C

| ANGII, nM | 0   | Los | 0   | Los |
|-----------|-----|-----|-----|-----|
| YAP       |     |     |     |     |
| Hoechst   |     |     |     |     |
Figure 3

A

|          | 5 min | 15 min | 30 min | 2 h  | 4 h  | 24 h  |
|----------|-------|--------|--------|------|------|-------|
| ANG      |       |        |        |      |      |       |
| pYAPS\textsuperscript{127} | ![Image](image1) | ![Image](image2) | ![Image](image3) | ![Image](image4) | ![Image](image5) | ![Image](image6) |
| pYAPS\textsuperscript{397} | ![Image](image7) | ![Image](image8) | ![Image](image9) | ![Image](image10) | ![Image](image11) | ![Image](image12) |
| YAP      | ![Image](image13) | ![Image](image14) | ![Image](image15) | ![Image](image16) | ![Image](image17) | ![Image](image18) |
| GAPDH    | ![Image](image19) | ![Image](image20) | ![Image](image21) | ![Image](image22) | ![Image](image23) | ![Image](image24) |

B

| ANGII, nM |          |        |        |      |      |       |
|-----------|----------|--------|--------|------|------|-------|
| 0         | ![Image](image25) | ![Image](image26) | ![Image](image27) | ![Image](image28) | ![Image](image29) | ![Image](image30) |
| .1        | ![Image](image31) | ![Image](image32) | ![Image](image33) | ![Image](image34) | ![Image](image35) | ![Image](image36) |
| .4        | ![Image](image37) | ![Image](image38) | ![Image](image39) | ![Image](image40) | ![Image](image41) | ![Image](image42) |
| .8        | ![Image](image43) | ![Image](image44) | ![Image](image45) | ![Image](image46) | ![Image](image47) | ![Image](image48) |
| 1.6       | ![Image](image49) | ![Image](image50) | ![Image](image51) | ![Image](image52) | ![Image](image53) | ![Image](image54) |
| 3.2       | ![Image](image55) | ![Image](image56) | ![Image](image57) | ![Image](image58) | ![Image](image59) | ![Image](image60) |
| 6.25      | ![Image](image61) | ![Image](image62) | ![Image](image63) | ![Image](image64) | ![Image](image65) | ![Image](image66) |
| 12.5      | ![Image](image67) | ![Image](image68) | ![Image](image69) | ![Image](image70) | ![Image](image71) | ![Image](image72) |
| 50        | ![Image](image73) | ![Image](image74) | ![Image](image75) | ![Image](image76) | ![Image](image77) | ![Image](image78) |

C

% of Maximum

D

E

| N. Targ. | ![Image](image79) | ![Image](image80) |
| siYAP   | ![Image](image81) | ![Image](image82) |
Figure 4

**A** IEC-6

**B** Caco-2

**C** HEK 293

**D** PANC-1

**Hoechst**

**YAP**

- ANGII
- FBS
- FBS
- NT

**kDa**

- ANGII
- FBS LPA
- FBS LPA
- NT

0 30 240 min 15 min 30 240 min 0 30 60 min

pYAPS$^{127}$ YAP
Figure 5

A

B

C

D

E

F

Figure 5
Figure 6
Figure 7

A

N. Targ.  siPKD  N. Targ.  siPKD

YAP

Hoechst

ANGII

B

N. Targ.  siPKD

Ratio Nuclear/Cytoplasmic

0  1.3  1.4  1.5  1.6  1.7

ANGII

C

kDa

75

75

75

100

100

37

-  ANGII

pYAPS^{127}
pYAPS^{397}
Total YAP
PKD C-20
PKD3
GAPDH

D

% of Maximum pYAPS^{127}

ANGII

0  20  40  60  80  100

N. T.  siPKD1  siPKD2  siPKD3  siPKD

siPKD

Figure 7
**Figure 8**

(A) Western blot analysis of proteins involved in the LATS2 pathway, showing changes over time with ANGII treatment. Proteins include pLATS-S909/872, pPKD-S916, pPKD-S744, PKD C-20, LATS2, and GAPDH. The blot is labeled with ANGII duration in minutes (0, 1, 2.5, 5, 10, 15, 30, 60).

(B) Same as (A) but with a different time course of ANGII treatment showing proteins pLATS-S909/872, pLATS-T1079/1041, pPKD-S916, pPKD-S744, PKD C-20, and GAPDH.

(C) Western blot analysis showing N. Targ. and siLATS2 conditions, with bands for pYAP-S127, pYAP-S397, Total YAP, pLATS-T1079/1041, pLATS-S909/872, LATS2, and GAPDH.

(D) Immunofluorescence images showing YAP and Hoechst staining under N. Targ. and siLATS2 conditions with and without ANGII treatment.

(E) Bar graph showing the YAP nuclear/cytoplasmic ratio with ANGII treatment.
Figure 9
Figure 11

(A) Images showing YAP and Hoechst staining in cells treated with LMB compared to control. (B) Graph showing the ratio of nuclear to cytoplasmic YAP in cells treated with LMB compared to control. (C) Bar graphs showing normalized AREG and CTGF mRNA levels in cells treated with ANGII and LMB. (D) Western blot showing the expression levels of pYAPS, pYAPS, Total YAP, pPKDS, pPKDS, PKD3, PKD C-20, and GAPDH. (E) Bar graphs showing normalized AREG and CTGF mRNA levels in cells treated with ANGII and LMB. (F) Diagram illustrating the proposed signaling pathways involving YAP, PKD, and AREG.
Biphasic regulation of Yes-associated Protein (YAP) cellular localization, phosphorylation and activity by G protein-coupled receptor agonists in intestinal epithelial cells: a novel role for protein kinase D (PKD)
Jia Wang, James Sinnett-Smith, Jan V. Stevens, Steven H. Young and Enrique Rozengurt

*J. Biol. Chem.* published online July 1, 2016

Access the most updated version of this article at doi: 10.1074/jbc.M115.711275

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts